File Name,Date of Response,Date Comments,Responding FDA Center,Response to Petition,Cited Statutes or Regulations,Justification for Response,Status of Review,Review Comments
FDA-2018-P-0033-0003_Petition_Response_Letter_from_FDA_CDER_to_Hyman__P.pdf,4/23/2018,,Center for Drug Evaluation and Research (CDER),"Dismissed (moot)
","- Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book)
- Orange Book Home
- Rasuvo Listing","The requested action (RLD designation for Rasuvo) had already occurred on December 18, 2017, before the petition was submitted on January 2, 2018, making the petition moot.

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0034-0004_Interim_Response_Letter_from_FDA_CDER_to_Hyman__Ph.pdf,6/27/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2) – Regulation governing FDA's obligation to respond to citizen petitions
","The FDA has not resolved the petition due to the need to address other Agency priorities. The interim response was issued in accordance with regulatory timelines.

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0034-0005_Agency_Response_Letter_from_FDA_CDER_to_Strides_Ph.pdf,8/30/2018,,Center for Drug Evaluation and Research (CDER),"Dismissed (moot)
","The document references the Orange Book but does not cite any specific statutes or regulations (e.g., CFR sections).
","FDA investigated claims that the current reference standard (ANDA 074655, Sandoz) for ranitidine hydrochloride capsules EQ 300 mg was unavailable or difficult to obtain. However, FDA determined there was an increase in distribution of the product after the petitions were submitted, and the product was currently being distributed. This rendered the petitions moot
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0097-0003_Interim_Response_from_FDA_CDER.pdf,7/2/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2) – This regulation governs interim responses to citizen petitions when the FDA has not reached a decision.
","FDA has not resolved the petition due to the need to address other Agency priorities. The response acknowledges the petition’s claims about access issues regarding the 1 g tablets of Amicar and notes that a final determination will follow when resources permit
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0098-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,7/17/2023,"No date recognized by ChatGPT, but found in signature line.",Center for Drug Evaluation and Research (CDER),Approved,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.94(a)(3)(iii)
- 505(j)(2)(A) and (B)
- 505(j)(2)(A)(iv)","The FDA found that:
• The proposed strength changes (150 mg, 200 mg, 300 mg) do not pose safety or effectiveness concerns.
• The uses, dose, dosage form, and route of administration are consistent with the listed drug (Zonegran®).
• If bioequivalence is demonstrated, the product can be expected to have the same therapeutic effect.
• Therefore, labeling changes or new safety/effectiveness investigations are not necessary",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0130-0007_Response_Letter_from_FDA_CDER_to_Lachman_Consultan.pdf,11/17/2023,"No date recognized by ChatGPT, but found in signature line.",Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)(i)
- Section 505B of the FD&C Act (PREA)
- 21 CFR 10.33 and 10.20","The requested change involves both a change in dosage form and strength, which triggered requirements under the Pediatric Research Equity Act (PREA). FDA determined that clinical trials are required and denied the waiver request for pediatric studies. Therefore, the petition could not be approved under the ANDA pathway
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0131-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,11/17/2023,"No date recognized by ChatGPT, but found in signature line.",Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)(i)
- Section 505B of the FD&C Act (PREA)
- Section 505(j)(2)(A) of the FD&C Act
- 21 CFR 10.33
- 21 CFR 10.20","The petition requested permission to submit an ANDA for zonisamide orally disintegrating tablets (various strengths), a change in dosage form and strength. This change triggered the Pediatric Research Equity Act (PREA). The FDA determined that clinical trials were required and denied the waiver request for those trials. As a result, the petition could not be approved under the ANDA pathway
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0258-0009_Letter_from_FDA_CFSAN_to_GILMAN_CHEESE_CORPORATION.pdf,7/12/2018,,Center for Food Safety and Applied Nutrition (CFSAN),Interim Response,"- 21 CFR §10.30(e)(2) – Pertaining to interim responses to citizen petitions
- 21 CFR §§133.169 and 133.170 – The petition targets amendments to these sections of cheese standards","Due to competing priorities including the FDA’s Nutrition Innovation Strategy (NIS), the agency has not resolved the petition within 180 days. The agency stated it will review the petition as part of efforts to modernize standards of identity and ensure they align with consumer dietary needs
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0266-0003_Response_Letter_from_FDA_CDER_to_Arent_Fox_LLP.pdf,7/16/2018,,Center for Drug Evaluation and Research (CDER),"Dismissed (moot)
","- No specific statutes or CFRs cited by number
- Orange Book referenced as the source for reference standards","The petitioner requested new reference standards for three fluocinolone acetonide products (ear, scalp, and body oils) due to market unavailability. However, the FDA confirmed that distribution resumed in April 2018, after the petitions were submitted. Therefore, the petition was rendered moot
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0268-0003_Response_Letter_from_FDA_CDER_to_Arent_Fox_LLP.pdf,7/16/2018,,Center for Drug Evaluation and Research (CDER),"Dismissed (moot)
","- No formal statutes or regulations (e.g., CFR or FDCA citations) are mentioned.
- The Orange Book is cited as the reference database.","The petitioner requested designation of new reference standards due to backorders of three Hill Dermaceuticals products (under NDA 019452). However, the FDA found that all three products resumed distribution in April 2018. As they are now actively being marketed, there was no need to designate new reference standards, making the petition moot
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0269-0003_Response_Letter_from_FDA_CDER_to_Arent_Fox_LLP.pdf,7/16/2018,,Center for Drug Evaluation and Research (CDER),"Dismissed (moot)
","No formal statutes or specific CFR citations were mentioned.
Reference was made to the Orange Book","The petitioner requested designation of new reference standards due to unavailability of three fluocinolone acetonide products. FDA investigated and found that distribution resumed in April 2018, rendering the petitions moot
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0322-0004_Final_Response_from_FDA_CTP.pdf,2/4/2022,,"Center for Tobacco Products (CTP)
","Dismissed (moot)
","- 21 CFR § 10.35(e) – Governs dismissal of petitions when circumstances render them moot
- 21 CFR § 10.75 – Pertains to supervisory review process","The petitioner (Commonwealth Brands, Inc.) requested a stay of seven NSE (Not Substantially Equivalent) orders to allow time for supervisory review. The CTP granted the appeal request, and subsequently issued SE orders for all products in question. As a result, the original request was considered moot, and the petition was dismissed under 21 CFR § 10.35(e)
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0327-0005_Letter_from_FDA_CDER_to_Fresenius_Kabi_USA__LLC.pdf,6/11/2018,,Center for Drug Evaluation and Research (CDER),Approved,"- 21 CFR § 314.161 – Determination if drug was withdrawn for safety/effectiveness
- 21 CFR § 314.162 – Removal of drugs from the Orange Book list
- 21 CFR § 10.30 – Citizen petitions","The petitioner requested confirmation on the status of Mutamycin (mitomycin) injectable, 5 mg/vial and 20 mg/vial under NDA 050450. FDA reviewed its records and found no evidence that the drug was withdrawn for reasons of safety or effectiveness. It reviewed postmarketing data and literature and found no adverse safety concerns. Therefore, FDA maintained the listing of the drug in the “Discontinued Drug Product List” in the Orange Book, allowing ANDAs to proceed
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0343-0003_Petition_Response_Letter_from_FDA_CDER_to_Fish___R.pdf,6/20/2018,,Center for Drug Evaluation and Research (CDER),Denied,"- 21 U.S.C. § 355(j) – Abbreviated New Drug Applications (ANDAs)
- 21 U.S.C. § 355(q) – Procedures for citizen petitions related to pending ANDAs
- 21 CFR § 314.92(a)(1) and § 314.94(a)(5) – Requirements for same active ingredient in ANDAs
- 21 CFR § 314.105, § 314.110, § 314.125, § 314.127, § 314.200 – Application review and procedural provisions","The petition requested that FDA refrain from approving an ANDA by Apotex referencing Zorvolex (diclofenac free acid), arguing that Apotex’s product used diclofenac sodium, a different active ingredient. FDA denied the petition, stating:
• The Agency is not required to issue final decisions on specific aspects of pending applications outside the standard review process.
• FDA emphasized the petitioner’s concerns may be valid (i.e., a product with a different active ingredient cannot be approved as an ANDA), but that determination must await full review of the specific application.
• As no final determination had been made on the ANDA at the time, addressing the issues raised would be premature.
• Therefore, the petition was denied without comment on the approval status of any specific ANDA
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0345-0006_Interim_Response_Letter_from_FDA_CDER_to_Macleods_.pdf,7/12/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR § 10.30(e)(2) – Regulation governing interim responses to citizen petitions
","The FDA stated that a final decision on the petition could not yet be made due to the need to address other agency priorities. The interim response was issued to comply with regulatory timelines, and the agency assured it would respond as soon as possible given its resource constraints
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0564-0006_Interim_Response_Letter_from_FDA_CFSAN_to_Panera__.pdf,8/27/2018,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Interim Response,"- 21 CFR § 10.30(e)(2) – Governs FDA’s requirement to provide interim response when unable to reach a decision within 180 days
","FDA stated that a final decision had not been reached due to competing agency priorities, including the Nutrition Innovation Strategy (NIS), and limited resources. The agency noted that it plans to modernize the standards of identity program, which includes reviewing petitions such as this one that requested a clearer definition of the term “egg” in 21 CFR § 160.100. FDA confirmed that a decision will be communicated once the review is complete
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0564-0007_Final_Response_Letter_from_FDA_CFSAN_to_Panera__LL.pdf,3/29/2022,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Denied,"- 21 U.S.C. § 341 – Definitions and standards for food
- 21 CFR § 130.5(b) – Petition requirements for food standards
- 21 CFR § 160.100 – General egg standard provisions
- 21 CFR §§ 160.105 – 160.190 – Standards for egg products
- 21 CFR § 101.4(b)(10)-(12) – Labeling of egg ingredients
- 21 CFR § 118.3 – Shell egg definition (for specific purposes)","The FDA denied the petition because:
• There is no statutory authority to define ""egg"" as a standard of identity under 21 CFR § 160.100.
• The petition did not provide evidence that current labeling practices mislead consumers.
• FDA regulations already require manufacturers to disclose additives.
• The proposal did not demonstrate that changes would promote honesty, fair dealing, or protect against economic adulteration.
• The request was not selected for standards modernization review
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0597-0004_Interim_Response_from_FDA_CDER_re_FDA_2018_P_0597.pdf,7/23/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR § 10.30(e)(2) – Regulation requiring interim responses to citizen petitions when a final decision cannot be made within 180 days
","FDA stated that it has not resolved the issues raised in the petition due to the need to address other Agency priorities. The agency committed to responding as soon as possible once a decision is made
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0597-0008_Letter_from_FDA_CDER_to_Alliance_for_Natural_Healt.pdf,7/3/2019,,Center for Drug Evaluation and Research (CDER),Denied,"- 21 CFR § 14.100(c)(17) – PCAC charter structure
- 21 U.S.C. § 353a(c)(1) – PCAC composition requirement under Section 503A
- 21 U.S.C. § 353b(c)(2) – PCAC composition under Section 503B
- 5 CFR § 2635.502(a) – Appearance issues guidance
- 21 CFR § 14.80(b)(1)(i) – Nomination standards
- FDA Draft Guidance on Appearance Issues and Conflicts of Interest","- Pew does not have a voting seat on the PCAC, contrary to the petition’s claim.
- The member cited (Elizabeth Jungman) served in an individual capacity, not as a representative of Pew.
- Jungman resigned from the PCAC on April 25, 2019, making the petition moot.
- The FDA rigorously screens PCAC members for both conflicts of interest and appearance issues. In Jungman’s case, no conflict or appearance issue was found.
- Members of the PCAC are selected for their individual expertise and do not represent their employers or organizations.
- The Agency emphasized the importance of maintaining integrity and balance in PCAC membership
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0598-0014_Petition_Denial_Letter_from_FDA_CDER_to_Kurt_Karst.pdf,7/6/2018,,Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 355(q))
- FDA regulations in 21 CFR Part 314
- Sections 505(c), 505(j), and 505(b)(2) of the FD&C Act","- FDA denied the petition without commenting on the approvability of specific ANDAs.
- The decision reflects FDA’s policy of not preemptively ruling on components of pending ANDAs before making a final decision on the ANDA as a whole.
- FDA emphasized the statutory and regulatory processes in place to evaluate and approve ANDAs, and noted that the petition did not justify bypassing these established review procedures.
- FDA noted that it must take action within 150 days under section 505(q), even if final decisions on the related ANDAs have not been made.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0599-0018_Interim_Response_from_FDA_OC_to_National_Pediculos.pdf,9/25/2018,,"Office of the Commissioner (OC)
",Interim Response,"- 21 CFR § 10.30(e)(2) – Regulation requiring interim responses when a final decision cannot be made within 180 days
","The petition requested revisions to FDA educational materials to promote lice combing—specifically the LiceMeister comb—as a valid option for head lice treatment. The FDA responded that the petition raises broader issues requiring further cross-agency review and analysis. Therefore, a final decision could not yet be made. FDA issued this interim response in compliance with regulations to inform the petitioner of ongoing consideration
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0599-0020_Final_Response_from_FDA_OC_to_National_Pediculosis.pdf,1/17/2020,,"Office of the Commissioner (OC)
",Partially Approved / Partially Denied,"- 21 CFR § 10.30(e)(2) – Citizen petition procedures
- 21 CFR § 807.92(a)(3) – Substantial equivalence for medical devices
- 21 CFR § 880.5960 – Classification for lice removal kits
- Section 510(k) of the FD&C Act – Premarket notification for devices","- Lice combs are regulated as class I exempt medical devices and the LiceMeister comb received 510(k) clearance in 1998.
- FDA agreed that combing is a valid method for managing pediculosis (head lice) and updated its website to reflect this.
- However, FDA denied the request to name LiceMeister specifically on the website, as it does not generally list brand names of exempt devices.
- FDA also found no scientific or regulatory basis to distinguish the LiceMeister from other lice combs and therefore denied the claim that it is “not equivalent” to other lice combs.
- The Agency also did not receive data to support claims that combing improves treatment safety or reduces drug-related risks, so these parts of the petition were denied
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0614-0003_Interim_response_from_FDA_DDM_to__GeneYork_Pharmac.pdf,8/6/2018,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR § 10.30(e)(2) – Governing interim responses to citizen petitions
","FDA stated it had not yet resolved the issues raised in the petition due to the need to address other Agency priorities. The Agency assured it would respond as soon as possible given the demands on its resources
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0614-0004_Letter_from_FDA_CDER_to_GeneYork_Pharmaceuticals_G.pdf,9/27/2019,,"Center for Drug Evaluation and Research (CDER)
","Dismissed (moot)
","No specific statutes or regulations are cited in the letter. However, it references the Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and includes a link to the database .
","The petitioner had requested FDA designate a new reference standard for Hexadrol (dexamethasone sodium phosphate). FDA explained that the Orange Book was recently updated to identify the exact product (ANDA 084916 by Fresenius Kabi) as the reference standard. Hence, the petition’s request had already been fulfilled, and it was dismissed as moot .

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0625-0007_Interim_Response_from_FDA_CDER_to_Made_in_the_USA_.pdf,8/7/2018,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR § 10.30(e)(2) – Regulation requiring interim response to citizen petitions when a final response is not ready within 180 days
","The petition requested FDA to initiate a rulemaking requiring pharmacies to label prescription drugs with their country of origin. FDA responded that the request raises complex issues requiring extensive review and analysis, and thus a final decision could not yet be reached. The interim response ensures compliance with regulatory timelines while a thorough review is ongoing
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0625-0008_Letter_from_FDA_CDER_to_Made_in_the_USA_Foundation.pdf,7/30/2019,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- 19 U.S.C. § 1304 – U.S. customs statute (marking requirements)
- 19 CFR § 134.1(d) – Customs definition of ""ultimate purchaser""
- 19 CFR § 134.46 – Marking requirements for imported articles
- 21 U.S.C. § 353(b)(2) – FD&C Act exemption for prescription drugs
- 21 CFR § 201.1(a) – Labeling regulations for name and address of manufacturer, packer, or distributor
- 21 U.S.C. § 331(a) – Prohibition of misbranded drugs","- The petition relied on customs law (19 U.S.C. § 1304) which is enforced by CBP, not FDA.
- CBP has jurisdiction to interpret what constitutes “ultimate purchaser” and whether markings are required.
- FDA does not interpret failure to state country of origin on pharmacy labels as misbranding under FD&C Act § 331(a).
- Under 21 CFR § 201.1(a) and 21 U.S.C. § 353(b)(2), pharmacy-dispensed prescriptions are exempt from labeling requirements regarding manufacturer information, so long as other statutory conditions are met.
- FDA emphasized that the choice of drug often depends on prescriber or pharmacist discretion, not consumer comparison of domestic vs. foreign origin.
- No evidence was provided that omission of origin labeling misleads consumers or poses safety concerns
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0664-0003_Interim_response_from_FDA_CDER_to_Prinston_Pharmac.pdf,8/7/2018,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR § 10.30(e)(2) – Governs interim responses when FDA cannot issue a final decision within 180 days
","The petition requested designation of ANDA 091115 (Rocuronium Bromide Injection) as a reference standard. FDA responded that it had not yet reached a decision due to the need to prioritize other agency matters. It issued this interim response in accordance with regulatory requirements and committed to respond as soon as resources allow
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0670-0008_Interim_Response_Letter_FDA_2018_P_0670.pdf,7/19/2018,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR § 10.30(e)(2) – FDA regulation on citizen petitions, requiring interim responses when final decisions are delayed
","- The petition, submitted on behalf of Paragon Bioteck, Inc., requested a determination that certain phenylephrine hydrochloride ophthalmic solutions under NDA 203510 and NDA 207926 are the “same” under FD&C Act § 736(a)(2)(B).
- FDA stated it had not yet resolved the issues in the petition due to the need to prioritize other agency matters.
- This interim response ensures compliance with procedural requirements while the agency continues evaluating the petition",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0673-0009_Interim_Response_from_FDA_CDER_to_Justice_for_Jake.pdf,8/7/2018,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR § 10.30(e)(2) – Regulation requiring interim responses to citizen petitions when final decisions are not issued within 180 days
","- The petition requested that alprazolam be reclassified from Schedule IV to Schedule II under the Controlled Substances Act, and that a study be conducted on its role in the opioid crisis.
- FDA responded that the petition raises complex issues needing extensive review and analysis, thus preventing a decision at that time.
- The letter was issued to comply with the procedural requirement for interim response under the applicable regulation
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0673-0011_Response_Letter_from_FDA_CDER_to_Justice_for_Jake.pdf,2/17/2021,,"Center for Drug Evaluation and Research (CDER)
",Partially Approved / Partially Denied,"- 21 U.S.C. § 360bbb-2
- 21 U.S.C. § 811
- Controlled Substances Act (21 U.S.C. § 801 et seq.)
- 21 U.S.C. § 812
- 21 CFR §§ 1300–1317
- Section 505(o)(4) of the FD&C Act
- Memorandum of Understanding with NIDA (50 FR 9518, March 8, 1985)","- Granted in part: FDA agreed to conduct a scientific and medical evaluation (eight-factor analysis) of alprazolam under 21 U.S.C. 811.
- Denied in part: FDA denied the request to reschedule alprazolam from Schedule IV to Schedule II because it does not have the statutory authority to take final scheduling action.
- FDA acknowledged the petition’s concern regarding alprazolam’s role in the opioid crisis and agreed to conduct an eight-factor analysis for potential rescheduling.
- However, FDA clarified that only DEA has the authority to reschedule controlled substances.
- Data reviewed included abuse, misuse, addiction, and overdose statistics, indicating that harms primarily occur when benzodiazepines are used with other substances.
- FDA has already taken steps to mitigate risks through labeling changes and public communication (e.g., boxed warnings, guidance for gradual tapering).",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0674-0007_Final_Response_Letter_from_FDA_CDER_to_Medtech_Pro.pdf,1/24/2024,"No date recognized by ChatGPT, but found in signature line.","Center for Drug Evaluation and Research (CDER)
",Approved,"- Section 505(j)(2)(C) of the FD&C Act
- 21 CFR § 314.93 – Suitability petition requirements
- 21 CFR § 314.93(e)(1) – Approval standards
- 21 CFR § 314.94(a)(3)(iii) – ANDA referencing requirement
- Section 505B of the Act (Pediatric Research Equity Act)
- Section 505(j)(2)(A) and (B) – ANDA submission requirements
- Section 505(j)(2)(A)(iv) – Bioequivalence","- FDA determined the change from tablet to powder form does not raise safety or efficacy concerns.
- Proposed use, dose, and route of administration match the listed drug.
- The change aligns with the approved labeling of the reference drug and meets bioequivalence expectations.
- Under PREA, studies were not required due to evidence that the drug would be ineffective or unsafe in all pediatric age groups, per Section 505B(a)(5).
- Approval of the petition does not guarantee ANDA approval, which is subject to further review.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0829-0003_Petition_Approval_Letter_from_FDA_CDER.pdf,4/13/2018,,"Center for Drug Evaluation and Research (CDER)
",Approved,"- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- 21 CFR § 314.3(b) – Definitions for listed drug and therapeutic equivalence
- 21 CFR § 314.94(a)(3) – ANDA bioequivalence requirement
- 21 CFR § 314.161(a) – Withdrawal of RLD
- 21 CFR § 314.122(a) – Conditions for using reference standards","- The original reference standard (Bactroban Calcium Cream, NDA 050746) was discontinued.
- Glenmark’s product (ANDA 201587) was selected as the new reference standard based on commercial availability and market leadership.
- FDA determined that the petitioners provided sufficient grounds for the change in designation
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0870-0007_Final_Response_Letter_from_FDA_CDER_to_Lachman_Con.pdf,7/17/2023,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- Section 505(j)(2)(C) of the FD&C Act
- 21 CFR § 314.93(e)(1)(vi) – Criteria for petition approval
- 21 CFR § 314.122(a) – RLD withdrawal conditions
- 21 CFR § 314.161(a) – RLD withdrawal review
- 21 CFR § 10.33 – Reconsideration of decisions
- 21 CFR § 10.20 – Petition format and submission","- The petition requested permission to submit an ANDA for Potassium Chloride ER Tablets USP, 8 mEq, citing a change in strength from the listed drug (20 mEq).
- FDA denied the petition because the same 8 mEq strength formulation was already approved in multiple NDAs (K-Tab and Klor-con).
- This disqualifies the petition under 21 CFR § 314.93(e)(1)(vi), which prohibits approval if an NDA already exists for the same change.
- FDA also noted the option to file for reconsideration or submit a new petition with additional information
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0874-0049_Interim_Response_Letter_from_FDA_CFSAN_to_Bonumose.pdf,8/17/2018,"Stamp dated August 17, but another stamp reflects August 20.","Center for Food Safety and Applied Nutrition (CFSAN)
",Interim Response,"- 21 CFR § 101.9(c)(6)(iii) – Nutrition labeling for added sugars
- 21 CFR § 101.9(c)(6)(iv) – Voluntary labeling for sugar alcohols
- 21 CFR § 10.30(e)(2) – Requirement for interim response to citizen petitions if no final decision is made within 180 days","- The petition requested that D-tagatose be exempted from classification as an added sugar and allowed to be voluntarily labeled like sugar alcohols.
- FDA explained that it could not reach a decision within the statutory timeline due to other priorities and limited resources.
- FDA committed to completing its review as warranted in context of its program priorities",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0874-0051_Interim_Response_Letter_from_FDA_CFSAN_to_Bonumose.pdf,8/17/2018,"Stamp dated August 17, but another stamp reflects August 20.","Center for Food Safety and Applied Nutrition (CFSAN)
",Interim Response,"- 21 CFR § 101.9(c)(6)(iii) – Nutrition labeling for added sugars
- 21 CFR § 101.9(c)(6)(iv) – Voluntary labeling for sugar alcohols
- 21 CFR § 10.30(e)(2) – Requirement for interim response to citizen petitions if no final decision is made within 180 days","- The petition requested that D-tagatose be exempted from classification as an added sugar and allowed to be voluntarily labeled like sugar alcohols.
- FDA explained that it could not reach a decision within the statutory timeline due to other priorities and limited resources.
- FDA committed to completing its review as warranted in context of its program priorities",FALSE,"Missing in original spreadsheet, so completed in full here. Appears to be a duplicate of FDA-2018-P-0874-0049_Interim_Response_Letter_from_FDA_CFSAN_to_Bonumose.pdf."
FDA-2018-P-0874-0053_Final_Response_to_Citizen_Petition_from_FDA_CFSAN_.pdf,5/18/2022,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Denied,"- 21 CFR § 101.9(c)(6)(iii) – Definition of ""Added Sugars""
- 21 CFR § 101.9(c)(6)(iv) – Voluntary declaration of sugar alcohols
- 21 CFR § 101.9(c)(6)(ii) – Definition of ""Total Sugars""
- 21 CFR § 101.60(c)(2) – Use of ""no added sugar"" labeling
- 21 CFR § 101.4(a)(1) and § 101.4(b)(20) – Ingredient labeling by common or usual name
- 21 CFR § 101.80 – Health claims for noncariogenic carbohydrate sweeteners","- Caloric Contribution: D-tagatose contributes 1.5 kcal/g, significantly more than allulose (0.4 kcal/g), and may add more ""empty calories"" to the diet.
- Labeling Integrity: FDA aims to prevent consumer confusion and maintain clarity; individualized declarations for multiple distinct sugars could clutter labels.
- Regulatory Consistency: D-tagatose fits the definition of ""added sugars"" under current regulations.
- Scientific Review: Although D-tagatose differs metabolically from traditional sugars, the FDA found insufficient basis to treat it differently without further rulemaking
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0876-0006_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,5/1/2023,"No date recognized by ChatGPT, but found in signature line.","Center for Drug Evaluation and Research (CDER)
",Approved,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR § 314.93 – Petitions for strength changes
- 21 CFR § 314.93(e)(1) – Grounds for approval
- 21 CFR § 314.94(a)(3)(iii) – Referencing the petition in ANDA submissions","- The proposed change in strength (200 mg to 400 mg) does not pose questions of safety or effectiveness.
- The dosage form, route of administration, and labeled uses are the same as the listed drug (Albenza® 200 mg).
- The proposed product aligns with dosing recommendations in the labeling.
- Bioequivalence demonstration would suffice to show therapeutic equivalence.
- No new investigations are required
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0877-0005_The_Food_Lawyers_Interim_Respons.pdf,6/13/2018,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Interim Response,"- 21 CFR § 101.9(c)(6)(i) – Pertaining to labeling of isolated and synthetic non-digestible carbohydrates with physiological health benefits
","- The petitioner requested inclusion of konjac flour (konjac glucomannan) in the list of non-digestible carbohydrates beneficial to health under 21 CFR § 101.9(c)(6)(i).
- FDA acknowledged the submission of prior studies and the intent to submit additional information.
- The agency indicated it needed more time to review the complete materials before issuing a decision
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0877-0010_Petition_Response_Letter_from_FDA_CFSAN_to_The_Foo.pdf,1/9/2020,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Approved,"- 21 CFR § 101.9(c)(6)(i)
- 21 CFR § 10.30(e)(3)
- Final rule: 81 FR 33742 (May 27, 2016)
- Guidance: Scientific Evaluation of the Evidence on the Beneficial Physiological Effects of Isolated or Synthetic Non-Digestible Carbohydrates Submitted as a Citizen Petition (21 CFR 10.30)","- The FDA reviewed the citizen petition and supplements submitted by The Food Lawyers, including extensive scientific literature.
- 26 studies were evaluated on glucomannan's effects on blood cholesterol; 9 were considered scientifically valid, and 6 demonstrated significant reductions in total and/or LDL cholesterol.
- Evidence shows that glucomannan has a physiological effect beneficial to human health, specifically by reducing blood cholesterol.
- FDA intends to exercise enforcement discretion for declaring glucomannan as dietary fiber on labels until the rulemaking process is completed.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0878-0006_Approval_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,4/11/2023,,"Center for Drug Evaluation and Research (CDER)
",Approved,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR § 314.93
- 21 CFR § 314.93(e)(1)
- 21 CFR § 314.94(a)(3)(iii)
- Section 505(j)(2)(A) and (B) and 505(j)(2)(A)(iv) of the Act","- The proposed change in strength (from 200 mg to 400 mg) does not raise safety or efficacy concerns.
- The dosage form, route, and labeled uses match the listed drug.
- The 400 mg tablet is consistent with the labeling of the listed drug.
- If bioequivalence is shown, the product will have the same therapeutic effect.
- No new investigations are required
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0884-0004_Interim_Response_Letter_from_FDA_CDER_to_Buchanan_.pdf,8/21/2018,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"21 CFR § 10.30(e)(2) – Governs the issuance of interim responses to citizen petitions
","The FDA stated it was unable to reach a decision on the petition due to the need to address other Agency priorities. The response assures that the FDA will reply fully once resources permit
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0884-0005_Response_Letter_from_FDA_CDER_to_Buchanan_Ingersol.pdf,2/19/2021,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- 21 CFR 314.70
- 21 U.S.C. 321(m)
- 21 U.S.C. 352(f)(1)
- 21 CFR 201.5
- 21 CFR 201.56(d)(1)
- 21 CFR 201.57(a)(11)
- 21 CFR 201.57(c)(7)
- 21 CFR 201.100(c)(1)
- 21 CFR 201.57(c)(3)(ii)
- 21 CFR 201.57(c)(7)(ii)(A)","- Trial Data Format: FDA determined that converting Trial 5 safety data into a tabular format and incorporating it into Table 2 was inappropriate due to limitations of cross-study comparisons and risk of implying untested comparative claims.

- 290 mcg Dose Data: Including the 290 mcg dose in Table 2 would suggest an unapproved dosing regimen for CIC, which is not indicated for this dosage. Existing labeling already communicates why this dosage is not recommended for CIC.

- Discontinuations: No evidence that adverse events (AEs) during temporary treatment pauses (up to 3 days) were excluded from reporting. Thus, proposed disclaimer was unnecessary.

- “Annoyance” Threshold: FDA found that adverse events were not filtered based on patient descriptions of severity (e.g., “annoyance”) and all reported AEs were recorded. The grading scale was only used to categorize severity, not to exclude events.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0945-0010_Interim_Response_Letter_from_FDA_CBER_to_Scott_Bea.pdf,8/16/2018,,"Center for Biologics Evaluation and Research (CBER)
",Interim Response,"21 CFR § 10.30(e)(2) – Pertains to FDA’s issuance of interim responses to citizen petitions
","FDA stated that it had not yet completed its response due to the need to address other priorities. A full response will be provided later
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0945-0012_Agency_Response_Letter_from_FDA_CBER_to_Scott_Beac.pdf,1/17/2020,,"Center for Biologics Evaluation and Research (CBER)
",Denied,"- 42 U.S.C. § 262(a)(2)(C)(i), § 262(i)(1), § 262(a) (Public Health Service Act)
- 21 CFR § 601.2(a), § 601.2(d), § 600.3(p), § 610.15(a) (FDA Biologics Regulations)","- Licensed vaccines must be demonstrated to be ""safe, pure, and potent"" per statutory and regulatory requirements.
- Aluminum salts (used as adjuvants) have a long history (80+ years) of demonstrated safety in billions of doses worldwide.
- FDA reviewed relevant studies and found no credible evidence showing harm from aluminum adjuvants in vaccines.
- Referenced studies (Shaw et al. and Mold et al.) had major methodological flaws or were not generalizable.
- FDA's own 2011 study showed the total aluminum exposure from vaccines in the first year of life is significantly below risk thresholds.
- WHO’s Global Advisory Committee on Vaccine Safety endorsed the FDA's aluminum safety assessment.
- Petition failed to provide evidence justifying a prohibition of aluminum adjuvants.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0964-0005_Agency_Response_Letter_from_FDA_CDER_to_Fresenius_.pdf,8/24/2018,,"Center for Drug Evaluation and Research (CDER)
",Approved (Determination Issued),"Not explicitly stated by citation number. However, the document references inclusion in the ""Discontinued Drug Product List"" of the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), which is governed by 21 CFR § 314.162.
","- The FDA reviewed its records regarding PLASMA-LYTE M AND DEXTROSE 5% (NDA 017390) and PLASMA-LYTE 148 AND DEXTROSE 5% (NDA 017451).
- It concluded that these products were not withdrawn from sale for reasons of safety or efficacy.
- Therefore, the products will remain listed in the Orange Book.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-0967-0005_Agency_Response_Letter_from_FDA_CDER_to_Fresenius_.pdf,8/24/2018,,"Center for Drug Evaluation and Research (CDER)
",Approved (Determination Issued),"Not explicitly stated by citation number. However, the document references inclusion in the ""Discontinued Drug Product List"" of the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), which is governed by 21 CFR § 314.162.
","- The FDA reviewed its records regarding PLASMA-LYTE M AND DEXTROSE 5% (NDA 017390) and PLASMA-LYTE 148 AND DEXTROSE 5% (NDA 017451).
- It concluded that these products were not withdrawn from sale for reasons of safety or efficacy.
- Therefore, the products will remain listed in the Orange Book.",FALSE,"Missing in original spreadsheet, so completed in full here. Appears to be a duplicate of FDA-2018-P-0964-0005_Agency_Response_Letter_from_FDA_CDER_to_Fresenius_.pdf."
FDA-2018-P-0998-0004_Letter_from_FDA_CDER_to_Hyman__Phelps___McNamara__.pdf,8/9/2018,,"Center for Drug Evaluation and Research (CDER)
",Approved (Determination Issued),"- 21 CFR 314.161
- 21 CFR 314.162
- Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7))
- Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)","- FDA reviewed its records and found no information indicating the drug (Prolixin tablets) was withdrawn for safety or effectiveness reasons.
- The petitioner presented no data suggesting a safety or efficacy concern.
- FDA independently evaluated postmarketing adverse events and literature and confirmed no evidence supporting withdrawal for safety/effectiveness. The drug was withdrawn voluntarily by the sponsor, not by FDA.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1014-0014_Petition_Response_Letter_from_FDA_CDER_to_Haynes_a.pdf,8/2/2018,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- Section 505(j) of the FD&C Act (21 U.S.C. § 355(j))
- 21 CFR §§ 314.3(b), 314.94(a), 314.127(a)(6)(i), 320.23(b), 320.24
- Case law including Schering Corp. v. FDA, Fisons Corp. v. Shalala","- Scientific Grounds: FDA found insufficient evidence to support petitioner’s claim that mycophenolate mofetil (the parent compound) could be accurately and reliably measured for BE studies.
- Regulatory Flexibility: Under the FD&C Act and FDA regulations, bioequivalence can be demonstrated through either parent compound or metabolite data, depending on scientific justification.
- Existing Guidance Adequacy: The current draft guidance already allows for the parent drug to be used in BE testing if it can be reliably measured, and defaults to metabolite data otherwise.
- Case-by-Case Review: FDA emphasized that whether parent compound data is necessary should be determined during review of specific ANDAs, not through a universal requirement.
- Lack of Evidence Against Approved Product: The petition failed to provide any data showing that the currently approved ANDA (203005) is not therapeutically equivalent or bioequivalent to the RLD.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1099-0004_Letter_from_FDA_CDER_to_Lachman_Consultant_Service.pdf,9/6/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2) – Pertains to interim responses to citizen petitions
","The FDA has not resolved the petition due to needing to address other agency priorities. The interim response complies with regulations and indicates they will respond as soon as possible.

",FALSE,
FDA-2018-P-1173-0034_Interim_Response_Letter_from_FDA_CDER_to_Alliance_.pdf,9/11/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,21 CFR 10.30(e)(2) – Regulation concerning interim responses to citizen petitions,"The petition raises complex issues requiring extensive review and analysis by FDA officials. An interim response was issued under applicable regulations.

",FALSE,
FDA-2018-P-1173-0036_Response_Letter_from_FDA_OC_to_Alliance_for_Natura.pdf,12/13/2022,"No date recognized by ChatGPT, but found in signature line.",Office of the Commissioner,Denied,"- 21 CFR 312.20(a) and 312.3(b) (IND submission requirements)
- 21 CFR 312.2(b)(1) (IND exemption criteria)
- 21 CFR 312.23, 312.40(b)
- 21 CFR 56, 50 (IRB and informed consent)
- 21 U.S.C. 321(ff), 331(ll) (FD&C Act dietary supplement definitions and restrictions)
- 21 CFR 10.115 (guidance practices)
- Proposed Rule: 87 FR 75536 (December 9, 2022) (IND exemption)","- The petition’s request to revise the IND guidance is being addressed through an ongoing rulemaking process, which the FDA finds to be a more efficient and comprehensive forum.
- FDA proposed new IND exemptions (self-determined and FDA-determined) for dietary supplement studies that meet specific safety, regulatory, and intent criteria.
- Finalizing the proposed rule would necessitate revising the IND guidance, thereby covering the concerns raised in the petition.
- Consequently, FDA declined to take separate action on the petition, instead inviting participation in the rulemaking process",FALSE,
FDA-2018-P-1174-0006_Final_Response_Letter_from_FDA_CDER_to_Pharma_Regu.pdf,1/16/2024,"No date recognized by ChatGPT, but found in signature line.",Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93(e)(1)(vi) (petition denial criteria)
- 21 CFR 10.33 and 10.20 (procedures for reconsideration)","The petition sought approval to submit an ANDA for Sildenafil Citrate Oral Suspension (10 mg/mL) by changing the dosage form. However, the FDA denied it because an NDA for the same change already exists: Liqrev® (sildenafil citrate) Oral Suspension, approved under NDA 214952. According to 21 CFR 314.93(e)(1)(vi), this precludes petition approval. 
",FALSE,
FDA-2018-P-1185-0007_Petition_Response_Letter_from_FDA_CVM_to_Provetica.pdf,6/13/2018,"No date recognized by ChatGPT, but found in signature line.","Center for Veterinary Medicine (CVM), specifically the Office of New Animal Drug Evaluation
",Approved,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 512(n)(3)(C) (approval criteria for suitability petitions)
- 21 CFR 514.5 (presubmission conference recommendations)","The petition proposed a change in dosage form (from chewable to meat-flavored soft tablet) for a generic ivermectin/pyrantel product. The FDA determined that:
- The proposed changes are permissible under a suitability petition.
- The changes do not require new safety or efficacy investigations.
- Therefore, the petition is approved under section 512(n)(3)(C) of the Act.
- However, this approval does not guarantee final approval of the ANADA, which must undergo a full review.",FALSE,
FDA-2018-P-1195-0006_Interim_Response_Letter_from_FDA_CDER_to_Kurt_Kars.pdf,9/13/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,21 CFR 10.30(e)(2) – Pertaining to interim responses to citizen petitions,"The FDA has not resolved the petition due to the need to address other Agency priorities. The response is interim and issued in compliance with 21 CFR 10.30(e)(2), with a commitment to respond once resources allow
",FALSE,"Missing in original spreadsheet, so completed in full here. This appears to be a duplicate file of FDA-2018-P-1195-0007_Interim_Response_from_FDA_CDER_to_Hyman__Phelps___.pdf."
FDA-2018-P-1195-0007_Interim_Response_from_FDA_CDER_to_Hyman__Phelps___.pdf,9/13/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,21 CFR 10.30(e)(2) – Pertaining to interim responses to citizen petitions,"The FDA has not resolved the petition due to the need to address other Agency priorities. The response is interim and issued in compliance with 21 CFR 10.30(e)(2), with a commitment to respond once resources allow
",FALSE,This appears to be a duplicate file of FDA-2018-P-1195-0006_Interim_Response_Letter_from_FDA_CDER_to_Kurt_Kars.pdf.
FDA-2018-P-1195-0008_Letter_from_FDA_CDER_to_Hyman__Phelps___McNamara__.pdf,5/8/2019,,Center for Drug Evaluation and Research (CDER),"Approved (Petition Granted)
","- 21 U.S.C. § 355(j) – Section 505(j) of the FD&C Act (ANDA requirements)
- 21 CFR 314.3(b) – Definitions of reference standard and listed drug
- 21 CFR 314.94(a)(3) – Reference standard selection
- 81 FR 69580, 69619 (Oct. 6, 2016) – Preamble to final rule on ANDAs and 505(b)(2) applications","- The petition requested that FDA designate ANDA 074190 (West-Ward's naproxen oral suspension, 25 mg/mL) as the new reference standard (RS) for Naprosyn.
- The current RS, NDA 018965 (Naprosyn), was found to be unavailable or not reliably available in the market for in vivo bioequivalence testing.
- West-Ward's ANDA 074190 is the only approved generic product that is therapeutically equivalent to the RLD and is listed in the Orange Book.
- Therefore, the FDA granted the petition and designated ANDA 074190 as the new RS. 
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1195-0012_Letter_from_FDA_CDER_to_Arnall_Golden_Gregory__LLP.pdf,7/12/2019,,Center for Drug Evaluation and Research (CDER),Denied (Petition for Stay),"- 21 CFR 10.35(e) – Governing criteria for granting an administrative stay of action
- 21 CFR 314.81(b)(2) – NDA sponsor reporting obligations
- 21 CFR 314.3(b) – Definitions of reference listed drug (RLD) and reference standard
- 81 FR 69580, 69619 (Oct. 6, 2016) – Final rule on ANDAs and 505(b)(2) applications","- The petition requested an indefinite stay of FDA’s May 8, 2019 decision to select ANDA 074190 (West-Ward) as the new reference standard for naproxen oral suspension.
- FDA concluded that the petitioner did not meet three out of the four mandatory criteria for granting a stay under 21 CFR 10.35(e):
    • No demonstration of irreparable injury
    • No sound public policy grounds
    • Delay would negatively impact public health and access to generics
- FDA emphasized the public interest in ensuring availability of a usable reference standard to support ANDA development.
- Therefore, the stay was denied, and FDA proceeded to update the Orange Book to reflect ANDA 074190 as the designated reference standard.",FALSE,
FDA-2018-P-1195-0016_Petition_Response_Letter_from_FDA_CDER_to_Arnall_G.pdf,5/26/2020,,Center for Drug Evaluation and Research (CDER),Denied,"- 21 CFR 10.33(d) – Criteria for granting reconsideration requests
- 21 CFR 314.3(b) – Definitions for reference listed drug (RLD) and reference standard
- 21 CFR 314.81(b)(2) – Annual report requirements for NDA holders
- 21 CFR 314.94(a)(3) – Reference standard use in ANDA submissions
- 21 U.S.C. § 355(j) – Section 505(j) of the FD&C Act (ANDA process)
- 21 U.S.C. § 356i(c) – Section 506I one-time marketing status report
- 81 FR 69580, 69619 (Oct. 6, 2016) – Final rule on ANDAs and reference standards","- FDA found no failure to consider or inadequacy in considering relevant information during the initial decision to designate ANDA 074190 as the new reference standard for naproxen oral suspension.
- Petitioners failed to submit timely and complete annual reports and NDC data, which are required under FDA regulations.
- Third-party commercial data showed no distribution of Naprosyn under NDA 018965, consistent with citizen petitions and contrary to the petitioners’ claims.
- FDA concluded that the selection of a new reference standard served the public interest by ensuring generic applicants could conduct required in vivo bioequivalence testing.
- FDA declined to grant reconsideration because it was not warranted under regulatory criteria or the public interest standard.",FALSE,
FDA-2018-P-1197-0003_Interim_Response_from_FDA_CDER_to_Exela_Pharma_Sci.pdf,9/13/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2) – Regulation for interim responses to citizen petitions
","- The petition from Exela Pharma Sciences requested that the FDA assign a therapeutic equivalence code “AP” to palonosetron hydrochloride IV solution (NDA 207963).
- FDA stated the issues raised were complex and required extensive review and analysis.
- The interim response was issued in accordance with 21 CFR 10.30(e)(2) to indicate that a final decision had not yet been made but would follow when possible.",FALSE,
FDA-2018-P-1263-0005_Interim_Response_Letter_from_FDA_CDER_to_Kratz___B.pdf,9/19/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2) – Regulation for issuing interim responses to citizen petitions
","- The petition, submitted on behalf of Rubicon Research Private Limited, requested designation of a suitable additional reference standard for diclofenac sodium delayed-release tablets (25 mg and 50 mg).
- FDA was unable to reach a decision due to the need to address other Agency priorities.
- The interim response was issued in compliance with 21 CFR 10.30(e)(2), which allows the Agency to acknowledge petitions that require further evaluation.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1263-0006_Letter_from_FDA_CDER_to_Kratz___Barry_LLP_and_Yili.pdf,11/26/2019,,Center for Drug Evaluation and Research (CDER),"Approved (Petition Granted)
","- 21 U.S.C. § 355(j) – Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.3(b) – Definitions (e.g., reference standard, RLD)
- 21 CFR 314.94(a)(3) – Requirements for ANDA submissions using reference standards
- 81 FR 69580, 69619 (Oct. 6, 2016) – Preamble to final rule on ANDAs and 505(b)(2) applications","- The petitions requested new reference standards for diclofenac sodium delayed-release tablets (25 mg, 50 mg, 75 mg) due to lack of availability of the current standards (ANDA 074376 and ANDA 074394 by CASI Pharmaceuticals).
- FDA verified through commercial data and regulatory filings that the current reference standards were unavailable on the market.
- Accordingly, FDA selected the following new reference standards based on availability and market leadership:
    - ANDA 090066 (Unique Pharmaceuticals) for 25 mg and 50 mg
    - ANDA 077863 (Unique Pharmaceuticals) for 75 mg.
- The decision ensures continuity and access for generic applicants seeking to establish bioequivalence.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1310-0044_Petition_Denial_Letter_from_FDA_CDER.pdf,5/17/2018,,Center for Drug Evaluation and Research (CDER),Denied,"- 21 U.S.C. § 355(j) – ANDA approval requirements under the FD&C Act
- 21 CFR 314.3(b) – Definitions (e.g., RLD, bioequivalence)
- 21 CFR 314.94(a) – ANDA content and format
- 21 CFR 320.24(b) – Bioequivalence testing methodologies
- 21 CFR 10.115 – Guidance practices and nonbinding recommendations
- 21 CFR 314.127(a)(6)(i) – Basis for refusing to approve an ANDA","- For Haynes and Boone Petition: The FDA disagreed that ANDAs relying on clinical endpoint studies should be denied. While such studies are the least accurate and reproducible method, they are still acceptable for locally acting drugs like sucralfate when properly designed. The withdrawal of the 2014 draft guidance does not preclude the use of clinical endpoint studies.
- For Vertice Petition: The FDA clarified that draft guidance does not impose binding requirements. The Agency will consider any scientifically valid alternative bioequivalence method proposed. Vertice’s requests were more suitable for public comment during the draft guidance process.
- The FDA emphasized it retains discretion to evaluate bioequivalence based on a “reasonable and scientifically supported criterion” and will consider methods on a case-by-case basis.",FALSE,
FDA-2018-P-1335-0004_Agency_Response_Letter_from_FDA_CDER_to_Hyman__Phe.pdf,8/23/2018,,Center for Drug Evaluation and Research (CDER),Approved (Determination Issued),"- 21 CFR 314.161 – Determination if a drug was withdrawn from sale for safety or effectiveness reasons
- 21 CFR 314.162 – Removal of listed drugs from Orange Book
- 21 U.S.C. § 355(j)(7) – Drug approval listings in the Orange Book","- The petition requested a determination under 21 CFR 314.161 whether Ditropan XL (oxybutynin chloride ER tablets), 5 mg, 10 mg, and 15 mg, had been withdrawn for safety or effectiveness.
- The FDA determined the 15 mg strength had not been withdrawn for such reasons after reviewing internal records and independent literature.
- The 5 mg and 10 mg strengths were already relisted in the Prescription Drug Product List, so no determination was needed.
- FDA's decision allows ANDAs referencing the 15 mg formulation to proceed, assuming all other regulatory requirements are met.",FALSE,
FDA-2018-P-1349-0007_Petition_Response_Letter_from_FDA_CVM_to_Douglass_.pdf,6/13/2018,"No date recognized by ChatGPT, but found in signature line.",Center for Veterinary Medicine (CVM),Approved,"- Section 512(n)(3) and 512(n)(3)(C) of the FD&C Act – Suitability petition criteria
- 21 CFR 514.5 – Presubmission conference recommendation","- The petition proposed a generic pimobendan compressed soft chewable tablet, differing in dosage form from the RLNAD Vetmedin® (hard chewable tablets).
- FDA determined that the proposed changes (soft vs. hard chewable form) are acceptable for a suitability petition under section 512(n)(3).
- No new safety or effectiveness studies are required for the generic product's proposed uses.
- Approval of the petition allows for submission of an ANADA; however, it does not guarantee eventual approval of the drug product.",FALSE,
FDA-2018-P-1351-0006_Agency_Response_Letter_from_FDA_CVM_to_Schafer_Vet.pdf,6/5/2018,"No date recognized by ChatGPT, but found in signature line.",Center for Veterinary Medicine (CVM),Approved,"- Section 512(n)(3) and 512(n)(3)(C) of the FD&C Act – Suitability petition provisions
- 21 CFR 514.5 – Presubmission conference guidance","- The petition proposed a generic marbofloxacin compressed chewable tablet in multiple strengths (25–200 mg), differing from the reference listed new animal drug (RLNAD) Zeniquin® Tablets, which are standard compressed tablets.
- FDA determined that this difference in dosage form is permissible under a suitability petition.
- No new studies on safety or effectiveness are required for this change.
- Approval of the petition permits submission of an abbreviated new animal drug application (ANADA), but does not guarantee approval of the final product.
- FDA encourages a presubmission conference to clarify application expectations.",FALSE,
FDA-2018-P-1352-0006_Agency_Response_Letter_from_FDA_CVM_to_Schafer_Vet.pdf,6/5/2018,"No date recognized by ChatGPT, but found in signature line.",Center for Veterinary Medicine (CVM),Approved,"- Section 512(n)(3) and 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act (FFD&CA)
- 21 CFR 514.5 – Presubmission conference guidance","- The petition proposed a generic marbofloxacin compressed soft chewable tablet, differing in dosage form from the RLNAD Zeniquin® Tablets (standard compressed tablet).
- The dosage strengths (25, 50, 100, 200 mg) and dosage schedules are consistent with the RLNAD.
- FDA found the proposed changes do not require new investigations into safety or efficacy.
- Therefore, the suitability petition was approved under section 512(n)(3)(C).
- FDA reminded the sponsor that approval of the petition does not guarantee approval of the abbreviated new animal drug application (ANADA), which must be submitted and reviewed separately.",FALSE,
FDA-2018-P-1361-0004_Agency_Response_Letter_from_FDA_CDER_to_Ajanta_Pha.pdf,8/23/2018,,Center for Drug Evaluation and Research (CDER),Approved (Determination Issued),"- 21 CFR 314.161 – Determination whether drug was withdrawn for safety or effectiveness
- 21 CFR 314.162 – List removals from the Orange Book
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7)) – Drug listing requirements","- The citizen petition requested confirmation that Ditropan XL (oxybutynin chloride) Extended Release Tablets, particularly the 15 mg strength, was not withdrawn for safety or effectiveness.
- FDA reviewed its internal records, literature, and post-marketing data and found no evidence of safety or efficacy concerns prompting withdrawal.
- As a result, the 15 mg tablets will remain listed in the “Discontinued Drug Product List” in the Orange Book, denoting a voluntary market withdrawal.
- This determination permits ANDA applications referring to Ditropan XL 15 mg to proceed, provided all other requirements are met.",FALSE,
FDA-2018-P-1441-0009_Response_Letter_from_FDA_CDER_to_Mr__Antell_and_Mr.pdf,10/4/2018,,Center for Drug Evaluation and Research (CDER),Denied,"- 42 U.S.C. § 262(a), (k), (l) – Pertaining to the approval and patent process for biologics under the Public Health Service (PHS) Act
- 35 U.S.C. § 271 – Patent law on infringement
- 42 U.S.C. § 262(a)(2)(C) – Manufacturing facility standards
- 42 U.S.C. § 262(l)(6)(C) – FDA role in biosimilar patent dispute notices","- The petition requested a public hearing to discuss the effects of court-ordered drug access restrictions, citing the case Baxalta v. Genentech over Hemlibra (emicizumab-kxwh).
- FDA explained that litigation outcomes and patent enforcement are outside FDA’s jurisdiction.
- While FDA acknowledges concerns about drug access and high prices, it emphasized it is addressing those through other mechanisms and policy initiatives.
- FDA concluded that a public hearing on this topic is not warranted under its statutory role in regulating safety, purity, and potency—not litigation or patent resolution.",FALSE,
FDA-2018-P-1448-0004_Letter_from_FDA_CDER_to_Hyman__Phelps___McNamara__.pdf,9/6/2018,Manually changed to September 6 from 8 (stamp was difficult to read).,Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(q) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 355(q))
- 2015 FDA Guidance for Industry: Abuse-Deterrent Opioids—Evaluation and Labeling","- The issues raised in the petition involve complex scientific and policy matters.
- These could not be resolved within the 150-day time frame mandated by law (section 505(q) of the FD&C Act).
- FDA supports development of abuse-deterrent opioids and is actively working with manufacturers and the public to advance this field.
- Postmarket studies are ongoing, and FDA takes a product-by-product approach in regulatory decisions.
- FDA reaffirmed the need for additional data and scientific development in this evolving area",FALSE,
FDA-2018-P-1453-0019_Response_from_FDA_CDER_to_Spear_Pharmaceuticals__I.pdf,9/6/2018,,Center for Drug Evaluation and Research (CDER),Denied,"- 21 C.F.R. § 320.24(b)(4)
- 21 U.S.C. § 355(j)
- 21 C.F.R. §§ 314.3(b), 314.94(a), 314.127(a)(6)(i), 320.1, 320.23(b), 320.24, 320.25(a)
- FD&C Act Section 505(j)(2)(A), (j)(2)(C), (j)(4), (j)(8)(B), and (j)(8)(C)
- Public Law 98-417 (Hatch-Waxman Amendments)","- The FDA affirmed its broad discretion under the FD&C Act and its regulations to determine bioequivalence methods on a case-by-case basis.
- The Agency stated it had not revised its draft guidance (June 2010) recommending in vivo clinical endpoint studies for fluorouracil cream.
- FDA reiterated it can consider scientifically valid alternative methods (e.g., in vitro) for demonstrating bioequivalence, as permitted under 21 CFR 320.24 and FD&C Section 505(j)(8)(C).
- Concerns raised by the petitioner (about variability in in vitro methods, cytotoxicity of the drug, and lack of scientific justification) were addressed, noting that FDA evaluates all scientific data and public comments during the guidance finalization process.
- FDA emphasized it had not made any changes to its product-specific guidance and denied the request to “reaffirm” prior requirements, affirming its flexibility to evolve guidance based on new scientific information.",FALSE,
FDA-2018-P-1469-0007_Final_Response_Letter_from_FDA_CDRH_to_Epstein_Bec.pdf,7/29/2024,,Center for Devices and Radiological Health (CDRH),Denied,"- 21 CFR 10.30(e) (FDA petition procedure)
- 21 CFR 882.5896 and 21 CFR 876.5340 (device classification regulations)
- FD&C Act Sections 513(a)(1), 513(f), 513(i)(1)(A), 510(k) (21 U.S.C. §§ 360c, 360k)
- 21 CFR 860.7(b), 807.87(f), 807.87(g) (device classification, premarket notification)
- Least Burdensome Provisions: Guidance for Industry and FDA Staff (2019)
- The 510(k) Program Guidance (2014)","- FDA found that the special controls already established in the De Novo orders (for NSS-2 BRIDGE and IB-Stim) under 21 CFR 882.5896 and 876.5340 were sufficient to provide reasonable assurance of safety and effectiveness.
- Petitioners requested a categorical requirement for additional animal and clinical testing, but FDA declined to impose such requirements across the board.
- FDA emphasized it may request additional data on a case-by-case basis in 510(k) reviews, depending on differences in device technology.
- Requiring such data for all new devices in the same classification would contradict FDA’s least burdensome principles and statutory flexibility in substantial equivalence determinations.
- Therefore, both petitions were denied because the requests were inconsistent with FDA’s established regulatory framework and policies.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1484-0007_Interim_Response_from_FDA_CDER__to_Macleods_Pharma.pdf,10/5/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) – Pertains to interim responses when final decisions on citizen petitions are delayed
","- The FDA states it has not resolved the issues raised in the April 12, 2018 citizen petition requesting designation of ANDA 080397 (isoniazid 300 mg by Barr Labs) as a reference standard in the Orange Book.
- FDA cites other agency priorities as the reason for the delay and confirms the response will follow ""as soon as possible.""",FALSE,
FDA-2018-P-1484-0008_Approval_Response_from_CDER_to_Macleods_Pharmaceut.pdf,8/15/2019,,Center for Drug Evaluation and Research (CDER),Approved,"- Section 505(j) of the FD&C Act (21 U.S.C. § 355(j))
- 21 CFR 314.3(b) – Definitions of therapeutic equivalents and reference listed drugs
- 21 CFR 314.94(a)(3) – ANDA content
- 21 CFR 320.22(c) – Bioequivalence waiver
- 21 CFR 320.24(b) – Bioequivalence standards","- The current reference standard for isoniazid 300 mg (NDA 008678 by Sandoz) was no longer commercially available.
- FDA determined, based on commercial distribution data, that ANDA 080937 (Barr) is the market leader and should replace NDA 008678 as the reference standard for 300 mg tablets.
- Similarly, ANDA 080936 (Barr) was designated the new reference standard for 100 mg tablets.
- Both NDA 008678 listings were moved to the Discontinued Drug Product List in the Orange Book.
- These actions ensure continued availability of reference standards for generic submissions.",FALSE,
FDA-2018-P-1484-0009_Updated_Response_Letter_from_CDER_to_Macleods_Phar.pdf,9/6/2019,,Center for Drug Evaluation and Research (CDER),Correction Notice,"- Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
- No specific statute (e.g., FD&C Act) is cited, though Orange Book criteria for bioequivalence standards are referenced indirectly","- The original citizen petition (April 12, 2018) requested FDA to designate ANDA 080937 (isoniazid 300 mg tablets by Barr) as the new reference standard.
- FDA previously responded on August 15, 2019, approving the petition, but mistakenly referenced the wrong ANDA number.
- This letter corrects that typographical error, affirming that ANDA 080937 is the correct new reference standard for isoniazid 300 mg tablets in the Orange Book.",FALSE,
FDA-2018-P-1516-0003_Letter_from_FDA_CDER_to_Encube_Ethicals_Private_Li.pdf,5/18/2018,,Center for Drug Evaluation and Research (CDER),Dismissed (moot),"- No specific statutes or regulations are cited by number. However, the following references were noted:
- Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book)
- Docket Nos. FDA-2017-P-3484, FDA-2017-P-6108, FDA-2018-P-0829","- The petition requested that mupirocin calcium cream, EQ 2% base, under ANDA 201587 (Glenmark) be designated as the reference standard in the Orange Book.
- FDA had already granted three prior petitions requesting the same action.
- As a result, FDA designated Glenmark's product as the reference standard and updated the Orange Book accordingly.
- Since the requested action was already completed, FDA dismissed this petition as moot.",FALSE,
FDA-2018-P-1531-0008_Denial_Letter_from_CDER_to_King___Spalding_LLP.pdf,11/16/2021,"No date recognized by ChatGPT, but found in signature line.",Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.93(e)(1)(vi)
- 21 CFR 10.33 – Procedures for reconsideration
- 21 CFR 10.20 – Petition format requirements","- The petition requested an ANDA for Ephedrine Sulfate Injection 25 mg/5 mL (5 mg/mL) syringes, referencing Akovaz 50 mg/1 mL.
- FDA noted that the exact requested strength had already been approved under NDA 208289 (also Akovaz).
- As per 21 CFR 314.93(e)(1)(vi), a petition cannot be approved if a product with the requested change is already approved under an NDA.
- FDA therefore denied the petition as moot. Petitioners may seek reconsideration within 30 days or submit a new petition with additional information.",FALSE,
FDA-2018-P-1532-0007_Petition_Denial_Letter_from_FDA_CDER_to_King___Spa.pdf,9/21/2021,"No date recognized by ChatGPT, but found in signature line.",Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.93(e)(1)(vi) – ANDA suitability petitions
- 21 CFR 10.33 – Reconsideration procedures
- 21 CFR 10.20 – Submission format requirements","- The petition requested approval to submit an ANDA for Ephedrine Sulfate Injection USP, 50 mg/10 mL (5 mg/mL) pre-filled syringes.
- The listed reference product was Akovaz 50 mg/mL (NDA 208289).
- FDA denied the petition because an NDA (213994 by Endo Ventures Ltd.) was already approved for the exact formulation (50 mg/10 mL or 5 mg/mL).
- Under 21 CFR 314.93(e)(1)(vi), a petition cannot be approved if an NDA for the same change already exists.",FALSE,
FDA-2018-P-1593-0051_Interim_Response_Letter_from_FDA_CFSAN_to_Pete_and.pdf,10/23/2018,,Center for Food Safety and Applied Nutrition (CFSAN),Interim Response,"- 21 CFR 101.65(d) – Related to the definition of “healthy” nutrient content claims
- 21 CFR 10.30(e)(2) – Concerning interim responses to citizen petitions
","- The petition requested FDA to amend 21 CFR 101.65(d) to allow eggs, as single-ingredient foods, to bear the label claim “healthy.”
- The FDA acknowledged it is still evaluating changes to the definition of “healthy.”
- The Agency received substantial public input through a 2016 Request for Information (RFI) and a 2017 public meeting, with over 1,200 comments.
- The Agency has not been able to resolve the petition within the required 180 days due to competing priorities and limited resources. FDA will continue to review the petition in the context of broader regulatory changes and public comments
",FALSE,
FDA-2018-P-1678-0006_Agency_Response_Letter_from_FDA_CDER_to__Mapi_USA_.pdf,12/28/2021,"No date recognized by ChatGPT, but found in signature line.",Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.93(e)(1)(vi) – Conditions under which ANDA suitability petitions can be denied
- 21 CFR 10.33 – Reconsideration procedures
- 21 CFR 10.20 – Petition format requirements","- The petitioner (Mapi USA, Inc.) requested FDA approval to submit an ANDA for Midazolam Injection 100 mg/100 mL (1 mg/mL).
- This would represent a change in strength from the listed drugs Versed 2 mg/2 mL and 5 mg/5 mL (both 1 mg/mL).
- However, FDA denied the petition because a drug product matching the requested formulation was already approved under NDA 211844 (Midazolam in 0.9% Sodium Chloride Injection, 100 mg/100 mL) by Inforlife SA.
- As per 21 CFR 314.93(e)(1)(vi), petitions must be denied if the requested change has already been approved via an NDA.",FALSE,
FDA-2018-P-1719-0006_Letter_from_FDA_CDER_to_Sciarra_Laboratories__Inc_.pdf,10/29/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) – Regulation allowing interim responses when a final decision has not been reached within 180 days
","- The petition requested that FDA designate Aeroseb-Dex (dexamethasone topical aerosol), 0.01%, approved under ANDA 083296 (held by Allergan Herbert), as a Reference Listed Drug (RLD) in the Orange Book.
- FDA has not yet completed review of the petition because it raises complex issues requiring extensive analysis. The agency will respond once a decision has been made
.
",FALSE,
FDA-2018-P-1720-0004_Letter_from_FDA_CDER_to_Gland_Pharma_Limited.pdf,11/16/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) – Regulation permitting interim responses when final action cannot be taken within 180 days
","- The petition, received on May 1, 2018, requested that FDA designate Furosemide Injection, 10 mg/mL, NDA # N018667 (Hospira) as the Reference Standard for development of a generic version of Furosemide Injection USP, 10 mg/mL.
- FDA has not reached a decision because it must attend to other agency priorities.
- The interim response acknowledges the delay and assures the petitioner that FDA will respond as soon as feasible, consistent with regulatory constraints and resource limitations",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1720-0005_Letter_from_FDA_CDER_to_Akorn_Pharmaceuticals__Myl.pdf,12/18/2018,,Center for Drug Evaluation and Research (CDER),"Mixed (One Petition Granted, Three Denied)
- Akorn Petition: Granted (designation of ANDA 202747 as RS)
- Mylan, Gland Pharma, Foley & Lardner Petitions: Denied","- 21 CFR 314.3(b) – Definitions of RLD and RS
- 21 CFR 314.94(a)(3) – Reference standard requirements
- 21 CFR 320.22(b)(1) – Bioequivalence waiver provisions
- FD&C Act, Section 505(j) (21 U.S.C. 355(j))","- The FDA reviewed four petitions requesting designation of various products as Reference Listed Drugs (RLDs) or Reference Standards (RS) for furosemide injection, 10 mg/mL.
- The Orange Book already identified two RLDs (NDAs 018579 and 016363), but both were discontinued.
- FDA determined it was appropriate to designate a new Reference Standard (RS) from available marketed products.
- Based on commercial availability and therapeutic equivalence, FDA selected ANDA 202747 (referenced in the Akorn petition) as the new RS.
- The other petitions either sought an additional RLD (which is unnecessary if two already exist) or proposed products FDA found insufficiently justified for RS designation.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1734-0003_Letter_from_FDA_CDER_to_Foley___Lardner__LLP.pdf,10/29/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) – Regulation permitting interim responses when final resolution is delayed beyond 180 days
","- The petition requested that FDA determine whether IC-GREEN (indocyanine green for injection) – in 10 mg/vial, 40 mg/vial, and 50 mg/vial strengths, under NDA 011525 by Akorn Inc. – has been withdrawn for safety or efficacy reasons.
- FDA has not yet made a decision due to the need to prioritize other agency matters. The agency promises to respond as soon as feasible, consistent with resource availability
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1734-0005_Letter_from_FDA_CDER_to_Foley___Lardner__LLP.pdf,12/12/2018,,Center for Drug Evaluation and Research (CDER),Approved (Determination Issued),"Not Mentioned – The letter does not cite specific statutes or regulations, though it references regulatory actions related to the Orange Book and the Federal Register notice.
","- The petitioner requested that FDA determine whether IC-GREEN (indocyanine green for injection), in strengths of 10 mg/vial, 40 mg/vial, and 50 mg/vial (NDA 011525), had been withdrawn from sale for reasons of safety or efficacy.
- FDA reviewed its records and concluded that IC-GREEN was not withdrawn for safety or effectiveness reasons.
- Accordingly, FDA will maintain the drug in the “Discontinued Drug Product List” section of the Orange Book, indicating it remains a valid reference listed drug for generic development
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1740-0006_Suitability_Response_Letter_from_FDA_CVM_to_Provet.pdf,8/8/2018,"No date recognized by ChatGPT, but found in signature line.",Center for Veterinary Medicine (CVM),Denied,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- Section 512(n)(3)(C) of the Act (basis for denial)
- 21 CFR Part 10 – General administrative procedures
- 21 CFR 10.33(e) – Reconsideration procedures for citizen petitions","- The petitioner requested approval to submit an Abbreviated New Animal Drug Application (ANADA) for a chewable deracoxib tablet for dogs that differed from the reference drug (Deramaxx™) in tablet scoring.
- Only the 12 mg and 100 mg tablets would be scored, unlike the RLNAD where all strengths are half-scored.
- The FDA considered the proposed dosing scheme too complex and potentially unsafe, especially because deracoxib is an NSAID with a narrow safety margin.
- The use of multiple tablet strengths and scored segments per dose increases the risk of dosing inaccuracies, and thus a target animal safety study would be needed.
- Because of these animal safety concerns, the petition was denied under section 512(n)(3)(C).",FALSE,
FDA-2018-P-1751-0004_Interim_Response_Letter_from_FDA_CDER_to_RegCon_So.pdf,10/31/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,- 21 CFR 10.30(e)(2) – Regulation that permits FDA to issue an interim response if a final decision cannot be made within 180 days,"- The petition, submitted on May 4, 2018, requested that the FDA update the Orange Book to designate Albuterol Sulfate Inhalation Solution, 2.5 mg/0.5 mL (ANDA 075664) by Nephron Pharmaceuticals as a reference standard.
- The FDA stated it was unable to decide due to other agency priorities.
- The agency provided this interim response in compliance with its regulations and promised to respond as soon as feasible, given its current demands",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1751-0005_Response_Letter_from_FDA__CDER_RegCon_Solutions_LL.pdf,1/31/2020,,Center for Drug Evaluation and Research (CDER),Approved,"- 21 U.S.C. § 355(j) (FD&C Act § 505(j))
- 21 CFR § 314.3(b)
- 21 CFR § 314.94(a)(3)
- 21 CFR § 320.22(b)(3)
- 81 FR 69580 at 69619 (Oct. 6, 2016)
- 72 FR 28982-28984 (May 23, 2007)","- The petition requested that the FDA amend the Orange Book to designate Nephron’s ANDA 075664 (Albuterol Sulfate Inhalation Solution, 2.5 mg/0.5 mL, 0.5% base) as a reference standard.
- FDA agreed because the current reference standard (ANDA 075050 by Bausch & Lomb) is not being marketed.
- NDA 019243 (Proventil) is listed in the ""Discontinued Drug Product List,"" but has not been withdrawn for safety or effectiveness reasons, so can be cited.
- The FDA found Nephron’s ANDA 075664 is the market leader and represents the most suitable candidate for use in bioequivalence studies",FALSE,"Response incorrectly identified by original, but updated to reflect accurate decision."
FDA-2018-P-1760-0005_Petition_Response_Letter_from_FDA_CDER_to_Serenity.pdf,6/21/2018,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted.",Center for Drug Evaluation and Research (CDER),Denied,"- 21 U.S.C. § 355(j) (Section 505(j) of the Federal Food, Drug, and Cosmetic Act)
- 21 CFR 314.127(a)
- 21 CFR 314.94(a)(9)
- 21 CFR 320.24(b)
- 21 CFR 320.22
- Orange Book Preface and related FDA Guidance Documents ","- Serenity’s petition requested that FDA: (1) require comparative clinical trials to establish bioequivalence of desmopressin nasal spray products to Noctiva; (2) refuse to accept any 505(j) application referencing Noctiva that lacks such clinical data; and (3) confirm that 505(b)(2) applications are required to have such data.
- FDA denied the petition on the grounds that:
• Clinical trials are not universally required for bioequivalence; they are one of several acceptable approaches.
• Generic applicants may propose alternative, scientifically justified bioequivalence methods, which FDA will evaluate.
• FDA does not determine the acceptability of a method prior to ANDA submission and instead evaluates it during review.
• The assertion that only a clinical trial would be acceptable lacks a scientific basis in this context.
- Thus, FDA concluded there was no basis to impose stricter standards for potential generics of Noctiva and denied all petition requests .",FALSE,
FDA-2018-P-1780-0004_Interim_Response_Letter_from_FDA_CDER_to_Pacira_Ph.pdf,11/2/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) — Regulation allowing interim responses when more time is needed for full consideration
","- The petition requested that FDA refrain from:
  1) Approving any NDA for a fixed-dose combination of bupivacaine and meloxicam unless supported by factorial studies and adequate evidence.
  2) Approving any NDA for the combination in a novel extended-release vehicle without safety data addressing potential risks.
- FDA stated it has not yet reached a decision due to the complexity of the issues and need for extensive review and analysis. Therefore, an interim response was issued per regulations",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1780-0005_Response_Letter_from_FDA_CDER_to_Pacira_Pharmaceut.pdf,5/21/2021,,Center for Drug Evaluation and Research (CDER),Partially Approved / Partially Denied,"- 21 CFR 300.50 – The “Combination Rule” for fixed-combination drugs (Page 3)
- 21 CFR 201.57(c) – Boxed warnings and safety labeling (Page 4)
- 21 CFR 314.50(d)(5)(v) – Approval with risk mitigation
- Section 505(d) of the FD&C Act (21 U.S.C. § 355(d)) – NDA requirements (Page 5)","- The petition sought to restrict NDA approval for HTX-011 (bupivacaine + low-dose meloxicam) based on concerns over efficacy evidence and safety (particularly inflammation and cardiovascular risks).
- FDA concluded that the Combination Rule requirements were satisfied, demonstrating that each component contributes to the overall effect.
- The agency found no new safety concerns significant enough to delay approval, citing clinical and nonclinical study data.
- Phase 2 and 3 data demonstrated that meloxicam enhances the effectiveness of bupivacaine.
- Boxed warnings and precautions were addressed through proper labeling consistent with other NSAIDs.
- The FDA therefore approved NDA 211988 for HTX-011 while declining to grant the full relief requested by the petition
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1846-0092_Interim_Response_Letter_from_FDA_DDM_to_Data_Based.pdf,11/6/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) — Regulation cited concerning interim responses for citizen petitions
","- The petition requested that the FDA require boxed warnings, warnings, precautions, and highlights of prescribing information for all selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)—including branded and generic versions—to warn of adverse sexual side effects.
- The FDA stated it has not yet made a decision due to the complexity of the issues, which require extensive review and analysis by agency officials.
- The agency committed to responding as soon as a final decision is reached",FALSE,
FDA-2018-P-1853-0003_Interim_Response_Letter_from_FDA_CDER_to_Aurobindo.pdf,11/2/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) — Regulation permitting interim responses to citizen petitions
","- The petition, submitted on behalf of Aurobindo Pharma Limited, requested FDA to designate a suitable alternative reference standard (ANDA #078572 held by Dr. Reddy's Laboratories) for conducting in vivo bioequivalence studies for Fluoxetine Delayed-Release Capsules USP, 90 mg.
- FDA was unable to reach a decision due to the need to address other Agency priorities.
- The Agency committed to issuing a final decision as soon as feasible
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1853-0004_Letter_from_FDA_CDER_to_AUROBINDO_PHARMA_USA__INC_.pdf,,No date recognized by ChatGPT nor apparent through a quick skim.,Center for Drug Evaluation and Research (CDER),Dismissed (moot),"- Not explicitly cited — The document references the Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book) but does not cite a specific statute or regulation
","- The petitioner requested a new reference standard for fluoxetine hydrochloride delayed-release capsules, 90 mg.
- At the time, the FDA reference was Eli Lilly’s product under NDA 021235.
- After the petition, Eli Lilly and Barr (ANDA 076237) discontinued their respective products.
- FDA updated the Orange Book and selected Dr. Reddy’s product (ANDA 078572) as the reference standard.
- Because the updates already fulfilled the petitioner’s request, the petition was deemed moot",FALSE,
FDA-2018-P-1869-0008_Interim_Response_Letter_from_FDA_CDER_to_Aurobindo.pdf,11/2/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) — Cited as the regulation governing interim responses to citizen petitions
","- The FDA has been unable to reach a decision due to the need to address other agency priorities.
- The petition requested the designation of an alternative reference standard (ANDA #085082 by Watson Laboratories) for bioequivalence studies on Dicyclomine HCl Capsules USP, 10 mg.
- The agency committed to responding as soon as possible considering the demands on its resources
",FALSE,
FDA-2018-P-1869-0009_Petition_Response_Letter_from_FDA_CDER_to_Aurobind.pdf,12/19/2019,,Center for Drug Evaluation and Research (CDER),Approved,"- 21 U.S.C. § 355(j) (FD&C Act, Section 505(j))
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)(3)
- 21 CFR 314.161
- 21 CFR 314.122
- Orange Book (Approved Drug Products With Therapeutic Equivalence Evaluations)
- 81 FR 69580 / 69619 (Oct. 6, 2016 Final Rule)","- The original reference standard, Bentyl (NDA 007409), is no longer available on the market.
- Petitioners demonstrated that the listed drug is unavailable and requested selection of a therapeutically equivalent product.
- The FDA reviewed commercial data, regulatory filings, and determined that ANDA 084285 (Lannett Co., Inc.) is the current market leader and therapeutically equivalent to the listed drug.
- Based on this, FDA concluded it is appropriate to designate ANDA 084285 as the new reference standard in the Orange Book
",FALSE,"Response incorrectly identified by original, but updated to reflect accurate decision."
FDA-2018-P-1876-0007_Letter_from_FDA_CDER_to_Sarfaraz_K__Niazi.pdf,11/16/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2)
","The FDA stated that the petition raises complex issues requiring extensive review and analysis by Agency officials. As such, they have not yet reached a decision and will respond as soon as one is made. 

",FALSE,
FDA-2018-P-1877-0005_Letter_from_FDA_CDER_to_Laurus_Labs_Limited_re_Cit.pdf,11/9/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2)
","The response notes that the petition remains unresolved due to the need to address other Agency priorities. FDA assures it will respond as soon as possible, given current resource demands
",FALSE,
FDA-2018-P-1877-0007_Letter_from_FDA_CDER_to_Laurus_Labs_Limited.pdf,2/4/2019,,Center for Drug Evaluation and Research (CDER),Approved (Determination Issued),"- 21 CFR 314.161 (Determination of withdrawal from sale for safety or effectiveness)
- 21 CFR 314.162 (Submission of labeling for ANDAs)
- Section 505(j)(7) of the FD&C Act (21 U.S.C. 355(j)(7))","FDA determined, based on a review of its records and Agency reports, that Esbriet (pirfenidone) 534 mg film coated tablets were not withdrawn from sale for reasons of safety or effectiveness. Therefore, they will remain listed in the ""Discontinued Drug Product List"" under the Orange Book, and may be referenced in Abbreviated New Drug Applications (ANDAs), provided all other requirements are met. This determination is essential for generic approval processes",FALSE,ChatGPT incorrectly recognized a negative result for whether a drug had been withdrawn for safety or efficacy reasons as a denial to the petition.
FDA-2018-P-1880-0005_Response_Letter_from_FDA_CDER_to_Louis_Morris_Aled.pdf,10/4/2018,"Date was originally incorrect, so have updated to be accurate",Center for Drug Evaluation and Research (CDER),Denied,"- Section 351(a)(2)(C) of the Public Health Service (PHS) Act
- 21 CFR 600.80 (Adverse Experience Reporting)
- Section 506B of the Federal Food, Drug, and Cosmetic Act (FD&C Act)","- Safety: FDA conducted an extensive review of adverse events including thrombotic microangiopathy (TMA), thromboembolic events, and deaths. The three reported TMA cases were associated with high doses of activated prothrombin complex concentrate (aPCC) and not with recombinant factor VIIa (rFVIIa). No additional TMA events were reported after protocol adjustments. The boxed warning was deemed adequate.

- Deaths: FDA reviewed five reported deaths and concluded they were unrelated to Hemlibra. An additional sixth death was also found to be unrelated.

- Antibody Concerns: One pediatric patient developed a neutralizing antibody with loss of efficacy, and this was updated in the product labeling.

- Efficacy: Hemlibra reduces bleeding rates but does not eliminate all bleeding risks. Life-threatening events may still occur, especially in patients with inhibitors.

- Boxed Warning: FDA found the existing boxed warning adequate and noted no new safety concerns requiring changes.

- Conclusion: FDA found Hemlibra to be safe, pure, and potent and noted that the benefits outweigh risks for Hemophilia A patients with limited treatment options. Therefore, the petition to revoke the license was denied.",FALSE,
FDA-2018-P-1892-0003_Interim_response__from_FDA_CDER_to__Aurobindo_Phar.pdf,1/24/2019,"Date was originally incorrect, so have updated to be accurate",Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2)
","The FDA has not reached a decision on the petition due to the need to address other Agency priorities. The interim response is issued in accordance with FDA regulations, and a final response will be provided as soon as possible given the demands on FDA resources
",FALSE,
FDA-2018-P-1892-0004_Petition_Response_Letter_from_FDA_CDER_to_Aurobind.pdf,12/19/2019,,Center for Drug Evaluation and Research (CDER),Approved,"- 21 U.S.C. § 355(j) (FD&C Act §505(j))
- 21 CFR § 314.3(b)
- 21 CFR § 314.94(a)(3)
- 21 CFR § 314.161
- 21 CFR § 314.122
- 81 FR 69580, 69619 (Final Rule, Oct. 6, 2016)","- Bentyl was unavailable for sale, though not discontinued in the Orange Book.
- FDA Drug Shortages database confirmed unavailability.
- ANDA 085223 is commercially available, therapeutically equivalent, and market-leading.
- Both petitions provided rationale to identify a new reference standard.
- FDA policy allows selection of an alternate reference when the listed drug is not available.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1949-0045_Petition_Response_Letter_from_FDA_CDER_to_Avadel_S.pdf,6/21/2018,,Center for Drug Evaluation and Research (CDER),Denied,"- 21 U.S.C. § 355(b), § 355(c), § 355(d) (FD&C Act Section 505)
- 21 CFR 314.125(b) – Grounds for refusal
- 21 CFR 314.126 – Adequate and well-controlled studies
- 21 CFR 314.52(a) – Patent certification requirements
- 21 CFR 314.3 – Definitions related to NDAs","- Substantial Evidence of Effectiveness: FDA concluded Ferring's resubmission of additional analyses from pivotal studies CS40 and CS41 demonstrated statistically significant and clinically meaningful benefit for patients with nocturia due to nocturnal polyuria.

- Benefit-Risk Balance: The benefits of NOCDURNA outweighed its risks when used per approved labeling, especially for patients with ≥2 nightly voids.

- Safety Database Adequacy: FDA determined Ferring's clinical trials sufficiently included older adults and patients with varying renal functions to evaluate safety.

- Bioavailability & Variability: FDA dismissed claims that NOCDURNA’s bioavailability or pharmacokinetic variability posed undue risks, concluding it was acceptable based on pharmacodynamic evidence and labeling guidance.

- No Patent Certification Required: FDA concluded NOCDURNA was submitted as a standalone 505(b)(1) NDA, not a 505(b)(2), and thus did not require patent certifications related to NOCTIVA.",FALSE,
FDA-2018-P-1966-0006_Response_Letter_from_FDA_CDER_to_McNeely__Hare___W.pdf,6/7/2023,"No date recognized by ChatGPT, but found in signature line.",Center for Drug Evaluation and Research (CDER),Approved,"- Section 505(j)(2)(C) of the FD&C Act
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)
- 21 CFR 314.93 – Petitions to request strength changes
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)","- The proposed strength change (150 mg and 300 mg) does not raise safety or efficacy concerns.
- The proposed drug uses the same dose, dosage form, and route of administration as the listed product.
- The change is consistent with existing labeling.
- If bioequivalence is shown, the product is expected to have the same therapeutic effect.
- No significant labeling changes or additional investigations are necessary to demonstrate safety and efficacy for the new strengths",FALSE,
FDA-2018-P-1980-0004_Letter_from_FDA_CDER_to_Foley___Lardner_LLP.pdf,11/16/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,- 21 CFR 10.30(e)(2) – Governs interim responses to citizen petitions when a final response is delayed,"- The Agency was unable to reach a decision on the petition due to the need to address other Agency priorities.
- The response was issued as an interim notification in compliance with regulatory procedures.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-1980-0005_Letter_from_FDA_CDER_to_Akorn_Pharmaceuticals__Myl.pdf,12/18/2018,,Center for Drug Evaluation and Research (CDER),"Mixed (One Petition Granted, One Denied)
- Akorn Petition: Granted (FDA designates ANDA 202747 as the reference standard for furosemide injection, 10 mg/mL)
- Mylan, Gland, and Foley & Lardner Petitions: Denied","- 21 U.S.C. § 355(j) – Section 505(j) of the FD&C Act
- 21 CFR 314.3(b) – Definitions of RLD and reference standard
- 21 CFR 314.94(a)(3) – Reference standards in ANDA submissions
- 21 CFR 314.125(b) – Grounds for denying ANDAs
- 81 FR 69580, 69619 (Oct. 6, 2016) – Final rule on ANDAs and 505(b)(2) applications","- FDA determined that identifying a new reference standard (RS) was appropriate because existing RLDs (NDA 018579 and NDA 016363) were discontinued.
- ANDA 202747, which is therapeutically equivalent to discontinued products and commercially available, was selected as the RS.
- The denied petitions did not provide sufficient grounds to designate additional RLDs or RSs, as current listings in the Orange Book already satisfied regulatory requirements for ANDA referencing.
- FDA emphasized that a new RS must ensure consistent bioequivalence testing, and availability played a key role in the designation decision",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2025-0013_Interim_Response_from_FDA_CDER_to_Center_for_Biolo.pdf,11/21/2018,"Date was originally incorrect, so have updated to be accurate",Center for Drug Evaluation and Research (CDER),Interim Response,- 21 CFR 10.30(e)(2) – Governs issuance of interim responses when a decision is delayed,"- The petition raises complex scientific and regulatory issues, including potential bans on oxybenzone and octinoxate in sunscreens and personal care products.
- The petition also requests:
1. Consultation with the National Marine Fisheries Service under Section 7 of the Endangered Species Act to assess impact on listed species.
2. Environmental analysis under the National Environmental Policy Act (NEPA).
- FDA needs more time for interagency coordination and review, thus providing an interim response.",FALSE,
FDA-2018-P-2050-0004_Letter_from_FDA_CDER_to_SS_Formulations__LLC.pdf,11/16/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) – Authorizes issuance of interim responses when final action is delayed
","- The petition, received on May 29, 2018, requests the FDA to issue a Monograph Change Notification for 2-hydroxy, monosodium salt (sodium salicylate) for use in skin products targeting hyperpigmented spots.
- FDA states it has not reached a decision due to the need to address other agency priorities and resource limitations.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2050-0005_Response_Letter_from_FDA_CDER_to_SS_Formulations__.pdf,12/2/2022,,Center for Drug Evaluation and Research (CDER),Denied,"- Section 505G of the FD&C Act (21 U.S.C. § 355h)
- Section 503(b)(1) of the FD&C Act (21 U.S.C. § 353(b)(1))
- Section 201(p)(1) of the FD&C Act (21 U.S.C. § 321(p)(1))
- Section 505G(b)(5)
- Section 744L(7) (21 U.S.C. § 379j–71(7))
- Section 505G(q)(3)","- The legal framework for evaluating over-the-counter (OTC) monograph changes has changed with the enactment of the CARES Act (March 27, 2020).
- FDA determined that such requests must now be submitted through the OMOR process, not via citizen petitions.
- As the petitioner qualifies as a “requestor” under section 505G(q)(3), they must follow the new statutory process for proposing monograph changes",FALSE,
FDA-2018-P-2073-0003_Interim_Response_Letter_from_FDA_CDRH_to_LMS_Direc.pdf,6/12/2018,,Center for Devices and Radiological Health (CDRH),Interim Response,- 21 CFR 10.30(e)(2) – Regulation allowing interim responses when final decisions are delayed,"- The petition, filed on May 30, 2018, requested a ban on all Laparoscopic and Hysteroscopic Power Morcellators for gynecological surgeries.
- FDA stated that the petition raises complex issues requiring further review and analysis before a final decision can be made
",FALSE,
FDA-2018-P-2073-0005_Response_Letter_from_FDA_to_LMS_Direc.pdf,12/30/2020,,"Center for Devices and Radiological Health (CDRH)
",Denied,"- Section 510(k) of the FD&C Act
- Section 516(a) of the FD&C Act (21 U.S.C. § 360f(a)) – Device bans
- 21 CFR 895.21(a) – Procedures for banning a device
- 21 CFR Part 803 – Medical Device Reporting (MDR)
- Section 519 of the FD&C Act (21 U.S.C. § 360i) – Reporting of device-related adverse events","- FDA reviewed all submitted and external scientific information and concluded that LPMs and hysteroscopic morcellators do not present a substantial deception or unreasonable and substantial risk that cannot be mitigated by labeling.
- The FDA has already implemented multiple risk mitigation strategies: updated labeling (2014, finalized 2020), safety communications (2014, 2017, 2020), advisory committee consultations, and requiring tissue containment systems for gynecologic use.
- FDA stated it lacks authority to amend Section 510(k) of the FD&C Act directly; however, existing postmarket surveillance regulations (e.g., MDR) provide mechanisms to monitor adverse events
",FALSE,
FDA-2018-P-2104-0004_Letter_from_FDA_CDER_to_Nostrum_Pharmaceuticals__L.pdf,11/27/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,- 21 CFR 10.30(e)(2) – Governs issuance of interim responses to citizen petitions when final decisions are pending,"- The petition requested the designation of ANDA 090430 as a reference standard for Theophylline ER tablets, 300 mg.
- The FDA stated that the petition raises complex issues needing extensive review and analysis, which has delayed a final response.",FALSE,
FDA-2018-P-2344-0006_Petition_Approval_Letter_from_FDA_CVM_to_Noble_Pha.pdf,9/6/2018,"No date recognized by ChatGPT, but found in signature line.",Center for Veterinary Medicine (CVM),Approved,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act (FFD&CA)
- Section 512(n)(3)(C) – Suitability petition approval standard
- 21 CFR 514.5 – Presubmission conference guidelines","- The proposed changes (from a compressed tablet to a scored soft chewable tablet) are acceptable under the suitability petition pathway.
- No additional investigations are required to demonstrate safety and efficacy for the intended use because the dosage and strength remain consistent with the RLNAD
",FALSE,
FDA-2018-P-2361-0005_Interim_Response_Letter_from_FDA_CDER_to_BF_Innova.pdf,12/14/2018,,Center for Drug Evaluation and Research (CDER),Interim Response,- 21 CFR 10.30(e)(2) – Governs the issuance of interim responses when final decisions on citizen petitions are delayed,"- The petition, received on June 18, 2018, requested the designation of Triamcinolone Acetonide (0.1%) cream, approved under ANDA 085692 (Fougera), as an additional reference listed drug in the Orange Book.
- FDA has not reached a decision due to the need to prioritize other agency responsibilities and resource demands
",FALSE,
FDA-2018-P-2408-0022_Agency_Response_Letter_fro_FDA_CDER_to_Public_Citi.pdf,2/21/2019,,Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(b) and 505(e)(2) of the FD&C Act (21 U.S.C. §§ 355(b), 355(e)(2))
- 21 CFR 10.30 – Citizen petition procedures","- The CARES trial and other data showed an increased risk of cardiovascular (CV) death with febuxostat compared to allopurinol, but FDA concluded that benefits outweigh risks for patients intolerant of allopurinol.
- Rather than removing febuxostat, FDA is requiring the following labeling changes:
- A boxed warning describing increased CV death risk.
- A change in indication to reserve febuxostat for patients who failed or cannot tolerate allopurinol.
- A Medication Guide to communicate CV risk to patients.
- FDA will also update its 2017 Drug Safety Communication, conduct outreach to professional societies, and require the sponsor to monitor post-market use of febuxostat
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2658-0003_Interim_response_from_FDA_CDER_to__Hyman__Phelps__.pdf,1/15/2019,"Date was originally incorrect, so have updated to be accurate",Center for Drug Evaluation and Research (CDER),Interim Response,- 21 CFR 10.30(e)(2) – Authorizes interim responses when final decisions on citizen petitions are pending,"- The petition, submitted on July 10, 2018, requests that FDA designate ANDA 078873 (methylphenidate hydrochloride extended-release capsules, 60 mg) as a reference standard for use in an abbreviated new drug application.
- FDA noted that the petition raises complex issues requiring extensive review and analysis, and a response will be issued once a decision is reached
",FALSE,
FDA-2018-P-2658-0004_Response_Letter_from_FDA_to_Hyman__Phelps__and_McN.pdf,11/18/2019,,Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(j) of the FD&C Act (21 U.S.C. § 355(j))
- 21 CFR 314.3(b) – Definitions of listed drug and reference standard
- 21 CFR 314.94(a)(3) – ANDA content requirements
- 21 CFR 314.125 – NDA/ANDA evaluations","- The current reference standard, Metadate CD (NDA 021259), is still being distributed as an authorized generic and has not been discontinued.
- FDA concluded that the petitions did not provide adequate grounds to select a new reference standard.
- FDA emphasized that an ANDA applicant may use the authorized generic version of the current RLD for in vivo bioequivalence studies, assuming appropriate documentation is provided.
- FDA does not believe selecting a new reference standard is warranted given the availability of the existing one in distribution",FALSE,"Information was off across the board, so updated most cells."
FDA-2018-P-2720-0003_Interim_response_from_FDA_CDER_to_Hyman__Phelps___.pdf,1/4/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) – Interim responses for citizen petitions when final decisions are delayed
","- The petition, submitted on July 13, 2018, requested that FDA amend the Orange Book to designate ANDA 204713 or another ANDA as a reference standard for benztropine mesylate tablets (0.5 mg, 1 mg, and 2 mg).
- FDA explained that a decision had not yet been reached due to other priority matters and resource demands
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2720-0004_Letter_from_FDA_CDER_to_Hyman__Phelps___McNamara__.pdf,4/24/2019,,Center for Drug Evaluation and Research (CDER),Approved,"- Section 505(j) of the FD&C Act (21 U.S.C. § 355(j))
- 21 CFR 314.3(b) – Definitions of listed drug, reference standard, therapeutic equivalents
- 21 CFR 314.94(a)(3) – ANDA content requirements
- 21 CFR 320.22(c) – In vivo bioequivalence waiver
- FDA Draft Guidance (Jan. 2017) – Referencing Approved Drug Products in ANDA Submissions","- The previous reference standard (ANDA 040103 by USL Pharma) is no longer marketed and will be moved to the Discontinued Section of the Orange Book.
- The RLD (NDA 009193 by Merck) is also discontinued and unavailable for sampling.
- Aspen’s ANDA 204713 is a therapeutic equivalent and the current market leader, thus appropriate to designate as the reference standard.
- Even though no in vivo bioequivalence studies are required for approval of an ANDA referencing Cogentin (benztropine), the FDA agreed a new reference standard would facilitate generic development
",FALSE,
FDA-2018-P-2749-0003_Interim_response_from_FDA_CDER_to_Anne_A__Shirinia.pdf,1/10/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) – Regulation authorizing interim responses to citizen petitions when final action is delayed
","- The petition (received July 17, 2018) requested that FDA issue strict guidelines on dosage and administration of prostate cancer chemotherapy medications, and monitor procurement of those medications.
- The Agency has not reached a decision due to the need to prioritize other demands on its resources and regulatory agenda",FALSE,
FDA-2018-P-2749-0004_Letter_from_FDA_CDER_to_Anne_A__Shirinian_Orlando_.pdf,6/4/2019,,Center for Drug Evaluation and Research (CDER),Denied,"- Section 201, 502(a), (f), and (j); and 505 of the FD&C Act (21 U.S.C. §§ 321(n), 352(a), (f), and (j); 355)
- 21 CFR 201.57(c)(3)(i)(H) – Labeling requirements
- 21 CFR 201.57(a)(7) – Prescribing information
- 21 CFR Part 210 and 211 – CGMP regulations
- Section 582 of FD&C Act (DSCSA)","- The petition asked FDA to mandate strict dosage and administration guidelines for prostate chemotherapy drugs (Zytiga, Jevtana, Xtandi) and ensure safe procurement of these drugs.
- FDA responded that existing drug labeling already includes required dosing guidance and adjustments for hepatic impairment per 21 CFR 201.57(c)(3)(i)(H) (see summaries on pages 2–3).
- Regarding procurement safety, FDA stated its current CGMP regulations, drug supply chain security laws, and educational outreach (e.g., “Know Your Source” program) are sufficient to address concerns about counterfeit or unsafe drugs.
- Therefore, FDA declined to take additional regulatory action beyond what is already in place
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2754-0004_Interim_response_from_FDA_CDER_to_Ascend_Laborator.pdf,1/10/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,- 21 CFR 10.30(e)(2) – Regulation authorizing interim responses to citizen petitions when final action is pending,"- The petition, received on July 17, 2018, requested that the FDA determine whether ONFI (clobazam) 5 mg tablets (NDA 202067) were withdrawn from the market for reasons related to safety or effectiveness.
- FDA issued this interim response due to resource constraints and competing priorities, indicating it will respond fully as soon as feasible",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2754-0006_Letter_from_FDA_CDER_to_Ascend_Laboratories.pdf,4/2/2019,,Center for Drug Evaluation and Research (CDER),Approved,"- Not explicitly cited in the letter (only references to the Orange Book and Federal Register notice).
","- FDA reviewed its records and concluded that ONFI (clobazam) 5 mg tablets (NDA 202067) were not withdrawn from sale for reasons of safety or effectiveness.
- Therefore, the product will remain listed in the Discontinued Drug Product List section of the Orange Book with Therapeutic Equivalence Evaluations.",FALSE,
FDA-2018-P-2755-0007_Interim_response_from_FDA_CDER_to_Ascend_Laborator.pdf,1/15/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) – Permits the issuance of interim responses when final decisions on citizen petitions are delayed
","- The petition, received on July 18, 2018, requested that FDA designate any other approved generic version of Metadate CD (methylphenidate hydrochloride ER capsules) as an alternate reference standard for submission of ANDAs.
- FDA has not yet reached a decision due to the complexity of the issues and indicated that it will respond as soon as a determination is made",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2755-0008_Response_Letter_from_FDA_to_Hyman__Phelps__and_McN.pdf,11/18/2019,,Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(j) of the FD&C Act (21 U.S.C. § 355(j))
- 21 CFR 314.3(b) – Definitions (e.g., listed drug, reference standard, therapeutic equivalents)
- 21 CFR 314.94(a)(3) – ANDA content requirements
- 21 CFR 320.22(c) – Bioequivalence waiver
- Section 505(t) – Authorized generics list","- Petitioners requested designation of another product as the reference standard for methylphenidate hydrochloride ER capsules, 60 mg.
- FDA reviewed its records and determined the current reference standard product (Metadate CD, NDA 021259) is still marketed as an authorized generic and not discontinued.
- FDA concluded there were no grounds to select a new reference standard since the existing one remains available for in vivo bioequivalence testing and market distribution.
- Therefore, FDA stated that selecting a new reference standard was not warranted",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2838-0010_Letter_from_FDA_CFSAN_to_Public_Citizen_s_Health_R.pdf,10/14/1999,,"Center for Devices and Radiological Health (CDRH)
",Approved,"- 21 CFR 888.3027 – Device classification for PMMA bone cement
- 21 CFR 860.7(c)(2) – Scientific evidence requirements
- 21 CFR 860.125 and 860.136(b)(5) – Panel consultation and reclassification procedures
- 21 CFR 314.94 – ANDA content requirements
- Section 513(a)(1)(B) and 513(a)(1)(B)(ii) of the FD&C Act (21 U.S.C. § 360c)
- 510(k) Guidance and ISO standards (e.g., ISO 5833, ISO 10993)","- The device was previously classified as a Class III “transitional device” (devices previously regulated as drugs).
- FDA determined that PMMA bone cement intended for orthopedic use (hip, knee, other joints) does not need premarket approval (Class III) but can be safely regulated under Class II with special controls, including consensus standards, guidance documents, and labeling requirements.
- The recommendation was supported unanimously by the Orthopedic and Rehabilitation Devices Panel, which reviewed safety/effectiveness data, clinical studies, and manufacturer submissions.
- Risks identified and addressed include cardiovascular reactions, hypersensitivity, improper handling, and post-operative complications. FDA concluded that general and special controls are sufficient to provide reasonable assurance of safety and effectiveness
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2838-0011_Final_Response_Letter_from_FDA_CFSAN_to_Public_Cit.pdf,2/5/2020,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Partially Approved / Partially Denied,"- 21 C.F.R. § 10.30(e)(3)
- 21 U.S.C. § 321(ff)
- 21 U.S.C. § 342(f)(1)(A)
- 21 U.S.C. § 371(a)
- 21 U.S.C. § 334(a)(1)
- 21 U.S.C. § 332(a)
- 21 U.S.C. § 352(f)(1)
- 21 U.S.C. §§ 331(d), 355(a)&(i)
- 21 U.S.C. § 321(g)(1)(B)
- Section 503A of FD&C Act (21 U.S.C. § 353a)
- Final Rule on Ephedrine Alkaloids (69 Fed. Reg. 6788)","- Issued safety alert in 2018 due to risks of cardiotoxicity, hypokalemia, and fatal arrhythmias from cesium chloride.
- Reviewed CAERS and FAERS databases and public comments.
- Found few current products and limited adverse event reports.
- Chose not to initiate rulemaking due to resource prioritization and available enforcement tools.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2851-0033_Denial_for_Citizen_Petition_from_Pharmaceutical_Ma.pdf,12/20/2019,,Center for Drug Evaluation and Research (CDER),Denied,"- FD&C Act (Federal Food, Drug, and Cosmetic Act):
• Section 505(b), 505(j), 505(b)(2), 505(q)(1)(F), 505(c)(1)(B), 505(d)
• Section 314 (21 CFR 314.50, 314.94, 314.105, 314.125, 314.127, 314.110, 314.200)
• Section 314.101(d)(9)
• Section 314.3(b), 314.162
- Administrative Procedure Act (cited in petition but refuted by FDA)
- 78 FR 23273 (Federal Register reference)","- Prematurity: FDA had not yet made decisions on Remoxy ER or other similar NDAs at the time of the petition.
- Procedural Framework: FDA emphasized statutory protections for applicants under the FD&C Act, requiring final decisions be based on full application reviews, not citizen petitions alone.
- Evaluation of Abuse-Deterrent Claims: FDA stated it only approves such claims when supported by appropriate scientific data; labeling explains deterrent properties without asserting absolute abuse prevention.
- Scientific Flexibility: FDA disagreed with the claim that its abuse-deterrent guidance is treated as binding, affirming that alternative approaches are accepted if justified by data.
- No Obligation to Approve or Deny Based on Petition Alone: FDA rejected calls to reject applications using 505(b)(2) pathways or to deny applications with specific study references, reiterating that these are handled via standard review protocols.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2862-0007_Interim_response_from_FDA_CDER_to__Lupin_Pharmaceu.pdf,1/18/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 C.F.R. § 10.30(e)(2)
","- FDA has been unable to reach a decision due to the need to address other Agency priorities.
- The response assures that the petition will be reviewed as soon as possible given resource constraints.",FALSE,
FDA-2018-P-2862-0008_Letter_from_FDA_CDER_to_Lupin_Pharmaceuticals__Inc.pdf,6/25/2019,,Center for Drug Evaluation and Research (CDER),Approved,"- Section 505(j) of the FD&C Act (21 U.S.C. § 355(j))
- 21 CFR 314.3(b) (definition of listed drug)
- 21 CFR 314.94(a)(3) (bioequivalence requirements)
- 21 CFR 314.94(a) (ANDA content)
- 81 FR 69580, 69619 (Final Rule on ANDAs and 505(b)(2) Applications)","- The existing reference standard (RS), Zithromax 600 mg tablet, was discontinued and thus not available in sufficient quantity for use in in vivo bioequivalence testing.
- The FDA reviewed regulatory filings and commercial data and confirmed that ANDA 065218 (Pliva) is the current market leader among generic drug products for Zithromax.
- Selecting a market-leading generic product as the new RS ensures availability and reliability for future ANDA applicants conducting bioequivalence studies",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2901-0003_Interim_response_from_FDA_CDER_to_Yiling_Pharmaceu.pdf,1/22/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) — Governs interim responses to citizen petitions when the Agency is unable to make a final decision within a set timeframe
","- The FDA has not been able to reach a decision due to the need to address other Agency priorities.
- The letter assures the petitioner that a final response will be provided as soon as possible, acknowledging resource constraints and workload demands.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2901-0004_Letter_from_FDA_CDER_to_Kratz___Barry_LLP_and_Yili.pdf,11/26/2019,,Center for Drug Evaluation and Research (CDER),Approved,"- 21 U.S.C. § 355(j) – Section 505(j) of the FD&C Act (regarding ANDAs)
- 21 CFR 314.3(b) – Definition of listed drug
- 21 CFR 314.94(a)(3) – Bioequivalence requirement for ANDAs
- 81 FR 69580, 69619 – Final rule on ANDA and 505(b)(2) applications (Oct. 6, 2016)","- FDA reviewed three petitions requesting the designation of new Reference Standards (RS) for diclofenac sodium delayed-release tablets due to market unavailability of existing RS products held by CASI Pharmaceuticals (ANDAs 074376 for 25 mg and 50 mg, and 074394 for 75 mg).
- FDA reviewed regulatory filings and third-party commercial data and determined that these products were discontinued or unavailable.
- FDA granted the petitions and selected:
• ANDA 090066 (Unique) as the new RS for 25 mg and 50 mg
• ANDA 077863 (Unique) as the new RS for 75 mg
— based on their status as current market leaders
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-2962-0003_Letter_from_FDA_CDER_to_Americans_for_Homeopathy_C.pdf,2/12/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) — FDA regulation concerning interim responses to citizen petitions when a final decision is delayed
","- The petition raises complex issues that require extensive review and analysis by Agency officials.
- FDA also cites the need to address other Agency priorities as a reason for the delay.
- FDA commits to respond once a decision is reached on the petition's content.",FALSE,
FDA-2018-P-2962-0005_Petition_Response_Letter_from_FDA_CDER_to_American.pdf,10/24/2019,,Center for Drug Evaluation and Research (CDER),Denied,"- Section 201(g)(1) and Section 201(p)(1) of the FD&C Act (21 U.S.C. §§ 321(g)(1), 321(p)(1)) — Definitions of “drug” and “new drug”
- 21 CFR 314.200 — Procedures for withdrawing approval
- 21 CFR 10.30 — Citizen petition regulations
- 21 CFR 314.126 — Adequate and well-controlled studies
- 21 CFR 314.200(c)(2)(iv) — Evidence for grandfather clause status
- CPG 400.400 — Compliance Policy Guide on Homeopathic Drugs","- Petition requests included: establishing a homeopathy advisory committee, converting CPG 400.400 to regulation, withdrawing FDA’s draft guidance on homeopathy, codifying that homeopathic drugs are not “new drugs,” and holding a public hearing before finalizing guidance.
- FDA rejected all requests, citing:
• Homeopathic drugs are not exempt from “new drug” provisions just because they comply with HPUS or USP standards.
• Monograph listing does not demonstrate safety or efficacy as required by FD&C Act.
• FDA cannot legally codify that homeopathic drugs are not “new drugs.”
• FDA cannot apply the 1938 “grandfather clause” broadly or without product-specific evidence.
• FDA’s risk-based enforcement strategy aligns with public health needs and will proceed.
• A public hearing was not granted, as prior public engagement (including 9,000+ comments and a 2015 hearing) was deemed sufficient.",FALSE,
FDA-2018-P-2985-0007_Petition_Approval_Letter_from_FDA_CVM_to_Norbrook_.pdf,10/12/2018,"No date recognized by ChatGPT, but found in signature line.","Center for Veterinary Medicine (CVM)
",Approved,"- Section 512(n)(3) and Section 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act (FFD&CA)
- 21 CFR 514.5 — Concerning presubmission conferences
","- The proposed change (from tablet to oral solution) is permissible under a suitability petition because:
• The dosage regimen (2.5 mg increments) is preserved.
• The change does not require new investigations into safety or effectiveness.
• The change qualifies under FFD&CA Section 512(n)(3).
- Approval of the petition does not guarantee ANADA approval, which is subject to separate FDA review.",FALSE,
FDA-2018-P-2997-0006_Interim_Response_from_FDA_OP_to_New_Civil_Libertie.pdf,2/1/2019,,"Office of the Commissioner, Policy Staff",Interim Response,"- 21 CFR 10.30(e)(2) — Pertaining to interim responses to citizen petitions when final decisions are delayed
","- FDA has not yet completed its response due to the existence of other FDA priorities.
- The interim response acknowledges the petition’s content (regarding FDA’s issuance of guidances) but defers final decision pending resource availability.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3076-0003_Interim_Response_Letter_from_FDA_CDER_to_Dr__Josep.pdf,1/31/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"- 21 CFR 10.30(e)(2) — Regulation governing interim responses to citizen petitions when a timely final decision cannot yet be issued
","- The petition requested that FDA allow “Avenanthramides” to be included among active ingredients under 21 CFR 347.10, as an alternative to colloidal oatmeal in skin protectant products.
- FDA has not completed its review due to the need to address other Agency priorities.",FALSE,
FDA-2018-P-3102-0069_Letter_from_FDA_CDRH_to_Richard_M__Fleming_Redacte.pdf,7/9/2019,,"Center for Devices and Radiological Health (CDRH)
",Denied,"- 21 CFR § 10.30(k) — Enforcement requests are outside the scope of citizen petition procedures
- 21 CFR § 10.45 — Denial of enforcement action is not final administrative action
","- The petition sought enforcement action against pharmaceutical and imaging companies for allegedly distributing misinformation and using inappropriate marketing.
- FDA states that requests for enforcement actions are outside the scope of citizen petition procedures.
- Complaints are reviewed, but decisions to pursue enforcement are discretionary and case-specific.
- CPT billing code concerns fall under CMS jurisdiction, not FDA.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3176-0004_Agency_Interim_Response_Letter_from_FDA_CDRH_to_Me.pdf,2/7/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Governs interim responses to citizen petitions when final decisions are delayed
","- The petition requested assignment of a therapeutic equivalence code “AP” in the Orange Book for Medefil’s new drug application 202832 (sodium chloride injection, USP, 0.9%) for the purpose of a prescription drug fee exception.
- FDA cited the need to address other Agency priorities as the reason for delay.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3176-0005_Final_Response_Letter_from_FDA_CDER_to_Medefil__In.pdf,12/20/2024,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- 21 CFR 314.3(b) — Definitions of pharmaceutical equivalence and bioequivalence
- 21 CFR 320.22(b) — Bioequivalence waiver criteria for parenteral solutions
- Section 505 of the FD&C Act (21 U.S.C. § 355) — Drug approval pathways
- Orange Book Preface — TE code assignment rules and definitions
- FDORA Section 3222 — Related to therapeutic equivalence requests for 505(b)(2) NDAs","- Pharmaceutical Equivalence & Bioequivalence: FDA agreed that Medefil’s product is pharmaceutically equivalent and bioequivalent to Hospira’s sodium chloride injection.
- User Interface Difference: Medefil’s product is packaged in a prefilled syringe, while Hospira’s product is in a flip-top vial.
— This design difference affects the user interface and may impact clinical effect or safety.
- Lack of Comparative Data: Medefil failed to submit adequate data comparing user interfaces, which is necessary to confirm therapeutic equivalence and assign the “AP” TE code. FDA cited draft guidance on comparative use human factors studies as relevant for such evaluations
",FALSE,
FDA-2018-P-3211-0004_Denial_letter_for_suitability_petition__from_FDA_C.pdf,11/15/2018,"No date recognized by ChatGPT, but found in signature line.","Center for Veterinary Medicine (CVM)
",Denied,"- Section 512(n)(3) and 512(n)(3)(C) of the Federal Food, Drug, and Cosmetic Act (FFD&C Act)
- 21 CFR Part 10 — General administrative procedures
- 21 CFR 10.33 — Procedures for requesting reconsideration of decisions","- The proposed product differed from the reference listed new animal drug (Equioxx® Oral Paste) in both dosage form (oral solution) and strength (11.4 mg/mL vs. 8.2 mg/g).
- Although such changes are eligible under a suitability petition, the proposed delivery system—a 130-mL multi-dose container—could enable extended use beyond the approved 14-day maximum.
- This raises target animal safety concerns, necessitating a target animal safety study, which disqualifies it from approval under section 512(n)(3)(C).",FALSE,
FDA-2018-P-3266-0006_Interim_Response_Letter_from_FDA_CDER_to_Haynes_an.pdf,2/21/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,- 21 CFR 10.30(e)(2) — Governs interim responses to citizen petitions when final decisions are delayed,"- The petition requests FDA to:
1. Withdraw the October 2017 Draft Guidance on Mycophenolate Mofetil oral suspension (which allows metabolite data alone to establish bioequivalence).
2. Permit use of both parent compound and metabolite data for establishing bioequivalence for abbreviated NDAs.
- FDA has not made a final decision due to the need to address other Agency priorities.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3266-0007_Final_Response_Letter_from_FDA_to_Haynes_and_Boone.pdf,11/21/2019,,"Center for Drug Evaluation and Research (CDER)
",Partially Approved / Partially Denied,"- 21 CFR 10.115(d) — Clarifies that guidance documents are non-binding recommendations
— Other references include FDA's Bioequivalence Recommendations for Specific Products (June 2010) and the Draft Guidance on Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA (December 2013)","- The petition challenged the October 2017 Draft Guidance that permitted use of metabolite-only data to establish bioequivalence for mycophenolate mofetil (MMF) oral suspension.
- FDA agreed to revise the guidance due to advancements in analytical methods, which now allow accurate and reliable measurement of both MMF and its metabolite.
- FDA denied the request where it interpreted the guidance as imposing requirements rather than providing recommendations (as per 21 CFR 10.115(d))
",FALSE,
FDA-2018-P-3281-0010_Letter_from_FDA_CDER_to_Pfizer_Essential_Health.pdf,2/15/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Regulation concerning interim responses to citizen petitions when a timely final decision cannot yet be issued
","- The petition requested FDA to issue guidance ensuring truthful and non-misleading communications by sponsors concerning the safety and effectiveness of biosimilars, including interchangeable biologics.
- FDA explains that the petition raises complex issues requiring extensive review and analysis, and it will respond once a decision is reached",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3281-0013_Final_Response_Letter_from_FDA_CDER_to_Pfizer_Esse.pdf,2/4/2020,,"Center for Drug Evaluation and Research (CDER)
",Partially Approved / Partially Denied,"- 21 CFR 10.115 — Good guidance practices regulation
- 21 CFR 10.115(h) — Comment process on guidance
- 21 CFR 10.30 — Citizen petition procedures
- 21 CFR 10.30(e)(2) — Interim responses
- Section 351(k) of the Public Health Service Act (PHS Act) — Biosimilar and interchangeable product licensing
- 21 CFR 202.1(e)(5) — Promotional labeling
- 21 CFR 601.12(a)(4) — Labeling changes for risk information","- FDA published a draft guidance titled Promotional Labeling and Advertising Considerations for Biological Reference and Biosimilar Products – Questions and Answers.
• The draft guidance provides considerations for presenting biosimilar data truthfully and non-misleadingly.
• FDA declined to address individual substantive requests (e.g., examples of misleading communications) at this time to allow public comment and future updates per good guidance practices.
- Petition is granted to the extent it requests issuance of draft guidance; denied in part for not addressing specific guidance content yet",FALSE,
FDA-2018-P-3284-0022_Response_Letter_from_FDA_CDER_to__Keryx_Biopharmac.pdf,1/19/2019,,"Center for Drug Evaluation and Research (CDER)
",Partially Approved / Partially Denied,"- Section 505(b)(2) and 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- Section 505(j)(7)(A)(i) (Orange Book listing)
- Section 505(c)(3)(E)(ii) (3-year exclusivity provision)
- Section 505(c)(3)(E)(ii) and (iii) (5-year exclusivity under Hatch-Waxman Amendments)
- 21 CFR 314.50(i)(5)
- 21 CFR 314.108 (exclusivity criteria)
- 21 CFR 314.94(a)(9)
- 21 CFR 10.115 (guidance practices)","- Denial of 5-Year NCE Exclusivity: FDA concluded that Auryxia (ferric citrate) contains a previously approved active moiety—free Fe³⁺ ion—which had been part of earlier FDA-approved drug products. Therefore, it is not eligible for 5-year exclusivity under the FD&C Act.
- Grant of 3-Year Exclusivity: The supplemental NDA (S-013) was based on new clinical investigations essential to approval (study in 234 adults with stage 3–5 non-dialysis dependent CKD), thereby qualifying for 3-year exclusivity under Section 505(c)(3)(E)(iii).
- Rejection of Additional Requests: FDA declined the request to revise the Ferric Citrate Draft Guidance and declined to require ANDAs to match specific ferric citrate ion complexes (2:2, 3:3, or hexaaquairon(III)) due to insufficient evidence for those specifications being critical to safety/efficacy",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3325-0018_Citizen_Petition_Denial_Response__from_FDA_CDER_to.pdf,1/24/2019,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- Section 505(b)(2) and 505(j) of the FD&C Act
- Section 505(j)(7)(A)(i)
- Section 505(c)(3)(E)(ii) and (iii)
- Section 505(j)(2)(A)(ii), (iii), and (iv)
- Section 505(j)(4)
- 21 CFR 314.94(a)(5)(i)
- 21 CFR 314.127(a)(3)
- 21 CFR 314.94(a)(10)
- 21 CFR 314.50(i)(5)
- 21 CFR 314.108
- FDA Draft Guidance: Conjugated Estrogens (2014)","- FDA concluded that Pfizer’s request for a new guidance using its own method (0.1% quantification of steroidal and non-steroidal compounds using LC-MS) was not warranted because FDA's Proposed Method, based on 60 steroidal components and USP standards, was scientifically adequate and reproducible across labs
.
- FDA stated it retains broad discretion in determining “sameness” of active ingredients under the Hatch-Waxman Amendments.
- FDA emphasized that issues raised by Pfizer should be submitted through the existing docket for public comments on the draft guidance, not through the petition mechanism
",FALSE,
FDA-2018-P-3354-0017_Letter_from_FDA_CDER_to_RUSH_UNIVERSITY_MEDICAL_CE.pdf,3/21/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Regulation governing interim responses to citizen petitions when final resolution is pending
","- The petition requested removal of boxed warnings from ultrasound contrast agent product labels.
- FDA has not yet made a decision because the petition raises complex issues requiring extensive review and analysis by Agency officials.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3355-0017_Interim_Response_from_FDA_CDER.pdf,3/1/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Regulation authorizing interim responses when timely final decisions cannot be issued
","- The petition requested that FDA reclassify Naloxone 4 mg Nasal Spray from prescription-only (Legend) to over-the-counter (OTC) status.
- FDA stated the issue raises complex scientific and policy questions that require further evaluation by Agency officials",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3355-0020_Final_Response_from_FDA_CDER_to_AllCare_Health.pdf,11/16/2022,,"Center for Drug Evaluation and Research (CDER)
",Partially Approved / Partially Denied,"- FD&C Act: Sections 505(b)(1), 505(b)(2), 505(j), 503(b)(1), 503(b)(4), and 505G (21 U.S.C. §§ 355, 355h)
- 21 CFR: §§ 310.200(b), 201.66
- PHS Act: Section 351 (42 U.S.C. § 262)
- Docket Notice: FDA-2022-N-446, Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use","- Granted: FDA has taken steps to facilitate the Rx-to-OTC switch of naloxone 4 mg nasal spray (e.g., developing model Drug Facts Labels, Federal Register notice).
- Denied: FDA cannot grant an immediate switch without sufficient product-specific safety and usability data
- Lack of sufficient product-specific data (label comprehension, human factors, actual use studies) needed for an immediate Rx-to-OTC switch.
- FDA is actively facilitating the switch by developing a model Drug Facts Label and publishing a Federal Register notice.
- A switch requires manufacturer participation and supporting data; the FDA cannot unilaterally reclassify products without this.
- The petition provided only general evidence, insufficient to satisfy regulatory standards",FALSE,
FDA-2018-P-3372-0008_Final_response_from_FDA_CDRH_to_Ohio_State_Univers.pdf,4/21/2021,,"Center for Devices and Radiological Health (CDRH)
",Denied,"- 21 CFR 882.5050 — Biofeedback devices
- 21 CFR 890.5360 — Measuring exercisers or interactive rehabilitation exercise devices
- 21 CFR 10.30(e) — General citizen petition regulation
- 21 CFR 860.123 — Reclassification petition content
- FD&C Act Sections:
- 513(e) (21 U.S.C. § 360c(e)) — Device reclassification
- 510(m)(2) (21 U.S.C. § 360(m)(2)) — Exemption from 510(k)
- 85 FR 44186 — Federal Register notice exempting certain devices","- The petition requested reclassification and expanded exemption for certain biofeedback devices under 21 CFR 882.5050.
- FDA determined that the requested action was not a reclassification, but rather a request to expand premarket notification exemptions, which should be submitted under section 510(m)(2).
- Additionally, FDA determined that the cited devices likely fall under 21 CFR 890.5360 (interactive rehabilitation exercise devices), not 882.5050.
- Devices under product code QKC (referenced by petitioner) were already exempt as of July 22, 2020.
- Therefore, FDA deemed the petition moot and denied it.",FALSE,
FDA-2018-P-3382-0004_Letter_from_FDA_CDER_to_Fresenius_Kabi_USA__LLC.pdf,3/8/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Governs FDA’s issuance of interim responses when additional time is needed for full evaluation
","- The petition requested designation of Sodium Chloride 0.45% in Plastic Container by Baxter Healthcare Corporation (NDA 018016) as an additional Reference Listed Drug (RLD).
- FDA indicated that due to competing priorities, it had not yet reached a decision, and the interim response was issued in accordance with regulatory procedures to acknowledge the delay
",FALSE,
FDA-2018-P-3382-0005_Letter_from_FDA_CDER_to_Fresenius_Kabi_USA__LLC.pdf,9/16/2020,,"Center for Drug Evaluation and Research (CDER)
",Dismissed (moot),"- Orange Book — Reference provided to the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations
","- The petitioner requested that sodium chloride injection 0.45% (450 mg/100 mL) approved under NDA 018016 be designated as an additional Reference Listed Drug (RLD) in the Orange Book.
- FDA confirmed it had already updated the Orange Book accordingly since the petition was submitted.
- Therefore, the Agency dismissed the petition as moot because the requested action had already been completed",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3401-0010_Agency_Response_Letter_from_FDA_CDER_to_Novo_Nordi.pdf,2/1/2019,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted.","Center for Drug Evaluation and Research (CDER)
",Denied,"- FD&C Act Sections:
- 505(j) (21 U.S.C. § 355(j)) – Abbreviated New Drug Applications (ANDAs)
- 505(b)(2) – NDAs relying partly on literature or prior FDA findings
- 505(k)(3) – Labeling regulations
- 702(a)(1) (21 U.S.C. § 372(a)(1)) – Inspections
- 706 (21 U.S.C. § 376) – Records
- 21 CFR §§:
- 314.50 – Content of NDA
- 314.94 – Content of ANDA
- 314.127 – ANDA approval/refusal criteria","- Novo Nordisk requested that FDA reject any ANDA or 505(b)(2) NDA referencing its liraglutide-containing products unless the applicant submitted clinical immunogenicity data.
- FDA declined to impose such a blanket requirement, stating that it determines whether clinical immunogenicity data are needed on a case-by-case basis and based on scientific evidence.
- FDA emphasized that definitive determinations on approvability of future applications would be premature, especially before finalizing its Peptide Draft Guidance.
- The agency also rejected the argument that it had improperly applied the APA by accepting ANDAs before the draft guidance was final .",FALSE,
FDA-2018-P-3412-0005_Letter_from_FDA_CDER_to_Aurolife_Pharma_LLC.pdf,3/4/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Regulation authorizing interim responses when the FDA cannot reach a timely decision on citizen petitions
","- The petition requested that FDA determine whether QVAR 40 and QVAR 80 (Beclomethasone Dipropionate HFA) have been withdrawn from sale for safety or efficacy reasons.
- FDA indicated that due to other agency priorities, it has not yet reached a decision on the petition.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3412-0007_Letter_from_FDA_CDER_to_Aurolife_Pharma_LLC.pdf,4/4/2019,,"Center for Drug Evaluation and Research (CDER)
",Approved (Determination Issued),"- Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) — particularly the ""Discontinued Drug Product List"" section (not a statute but a critical regulatory reference mentioned)","- FDA reviewed the records and concluded that QVAR 40 and QVAR 80 were not withdrawn from sale for safety or effectiveness reasons.
- Therefore, they would remain listed in the Orange Book under the ""Discontinued Drug Product List"" with their therapeutic equivalence evaluations
",FALSE,
FDA-2018-P-3413-0003_Letter_from_FDA_CDER_to_Pharmaceutical_R___D_and_Q.pdf,3/4/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Governs the issuance of interim responses to citizen petitions when final decisions are delayed
","- The petition requested that FDA designate a new reference standard for ANDA 085475 (chlordiazepoxide HCl capsules, USP 5 mg, 10 mg, and 25 mg, held by Valeant Pharmaceuticals International).
- FDA stated it had not reached a decision due to competing agency priorities.",FALSE,
FDA-2018-P-3422-0005_Letter_from_FDA_CDER_to_NOVITIUM_PHARMA_LLC.pdf,3/4/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Regulation permitting interim responses when additional time is needed to resolve citizen petition issues
","- The petition requested that FDA designate the generic product made by PAR Pharmaceutical Inc. (A077827) as the reference standard for Oxandrin Tablets (NDA 013718).
- FDA explained that the petition involves complex issues requiring further review and analysis by Agency officials.",FALSE,
FDA-2018-P-3426-0004_Response_Letter_from_FDA_CDER_to_Pharmax_Group__In.pdf,3/15/2019,,"Center for Drug Evaluation and Research (CDER)
",Approved,"- 21 U.S.C. § 355(j) (Section 505(j) of the FD&C Act)
- 21 CFR 314.3(b) — Definitions of listed drug, reference standard, and therapeutic equivalents
- 21 CFR 314.94(a)(3) — Requirements for ANDA content
- 21 CFR 320.22(c) — Bioequivalence waiver","- The current reference standard (ANDA 087056 held by Ivax) was no longer marketed and moved to the “Discontinued Drug Product List.”
- The proposed alternative (ANDA 040644 held by Boscogen) was therapeutically equivalent and the market leader by volume.
- Although no in vivo studies were required, the new RS designation would be beneficial for product development and consistency",FALSE,
FDA-2018-P-3545-0006_Letter_from_FDA_CDER_to_Arnall_Golden_Gregory__LLP.pdf,3/19/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Regulation allowing the FDA to provide an interim response when more time is needed to reach a decision
","- The petition requested that FDA enforce Import Alert #66-40 and deny admission of Emcure's BiCNU® product until the company resolves quality-related deficiencies cited in a March 3, 2016 Warning Letter.
- FDA indicated that the matter involves complex issues requiring extensive review and analysis by agency officials",FALSE,
FDA-2018-P-3597-0005_Letter_from_FDA_CDER_to_ARENT_FOX_LLP.pdf,2/15/2019,"Date was originally incorrect, so have updated to be accurate","Center for Drug Evaluation and Research (CDER)
",Approved,"- Orange Book – Specifically, the “Discontinued Drug Product List of Approved Drug Products With Therapeutic Equivalence Evaluations” is cited. No specific statutes or CFR regulations are mentioned
","- Based on its records, FDA determined that LOTRIMIN (clotrimazole) topical solution was not withdrawn for safety or effectiveness reasons.
- Thus, it will remain listed in the Orange Book with therapeutic equivalence evaluations",FALSE,
FDA-2018-P-3599-0003_Letter_from_FDA_CDER_to_AuroMedics_Pharma_LLC.pdf,3/20/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Regulation under which the interim response is issued when a final response is delayed
","- The petition requested that FDA (1) determine whether the original formulation of Kenalog-10 (NDA 12041) was discontinued for safety or effectiveness reasons, and (2) accept ANDAs referencing the original formulation.
- FDA cited the need to address other Agency priorities before making a decision",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3599-0004_Citizen_Petition_Approval_Letter_from_FDA_CDER_to_.pdf,7/4/2021,,"Center for Drug Evaluation and Research (CDER)
",Approved,"- 21 U.S.C. § 355(j) (FD&C Act section 505(j))
- 21 CFR § 314.3(b)
- 21 CFR § 314.94(a)(9)(ii) and (iii)
- 21 CFR § 314.127(a)(8)(ii)(B)
- 21 CFR § 314.122(a)
- 21 CFR § 314.161(a)(1)
- 21 CFR § 314.99(b)","- FDA found no evidence that the original formulation of Kenalog-10 (approved prior to October 23, 2015) was discontinued for reasons of safety or effectiveness.
- FDA independently reviewed relevant literature and adverse event data and found no concerns related to the prior formulation.
- FDA confirmed it may accept and approve ANDAs duplicating the discontinued Kenalog-10 formulation, provided they meet applicable statutory and regulatory requirements.
- FDA may waive certain regulatory requirements under 21 CFR § 314.99(b), specifically regarding inactive ingredients in parenteral drugs, if justified by safety and regulatory precedent.",FALSE,
FDA-2018-P-3616-0010_Letter_from_FDA_CDER_to_Suven_Life_Sciences_Limite.pdf,3/19/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Permits the FDA to issue interim responses when more time is needed to decide on citizen petitions
","- The petition requested designation of a new reference standard for chloroquine phosphate tablets 250 mg (EQ 150 mg base).
- FDA stated that due to other Agency priorities and demands on resources, a decision has not yet been made
",FALSE,
FDA-2018-P-3616-0011_Response_Letter_from_FDA_CDER_to_Suven_Life_Scienc.pdf,2/19/2020,,"Center for Drug Evaluation and Research (CDER)
",Approved,"- 21 U.S.C. § 355(j) (FD&C Act section 505(j))
- 21 CFR § 314.3(b)
- 21 CFR § 314.94(a)(3)
- Abbreviated New Drug Applications and 505(b)(2) Applications (81 FR 69580 at 69619, October 6, 2016)","- The current reference standard (ANDA 083082) was no longer marketed and should be moved to the Discontinued Drug Product List.
- The proposed alternative, ANDA 091621, is therapeutically equivalent and currently marketed.
- Commercial and regulatory data supported selecting a new reference standard to ensure availability for bioequivalence studies
",FALSE,
FDA-2018-P-3640-0008_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,5/24/2019,,Center for Food Safety and Applied Nutrition (CFSAN),Interim Response,"- 21 CFR 10.30(e)(2) — Allows for interim responses if a decision cannot be made within 180 days
","- FDA has not been able to reach a decision due to other agency priorities and limited resources.
- The petition requested a regulation to prohibit the term “Non-GMO” on labeling of consumer foods and goods",FALSE,"Missing in original spreadsheet, so completed in full here. Appears to be a duplicate file of FDA-2018-P-3640-0009_Interim_Response_Letter_from_FDA_CFSAN_to_Informat.pdf"
FDA-2018-P-3640-0009_Interim_Response_Letter_from_FDA_CFSAN_to_Informat.pdf,5/24/2019,,Center for Food Safety and Applied Nutrition (CFSAN),Interim Response,"- 21 CFR 10.30(e)(2) — Allows for interim responses if a decision cannot be made within 180 days
","- FDA has not been able to reach a decision due to other agency priorities and limited resources.
- The petition requested a regulation to prohibit the term “Non-GMO” on labeling of consumer foods and goods",FALSE,"Missing in original spreadsheet, so completed in full here. Appears to be a duplicate file of FDA-2018-P-3640-0008_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf."
FDA-2018-P-3666-0003_Letter_from_FDA_CDER_to_Fresenius_Kabi_USA__LLC.pdf,3/21/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"- 21 CFR 10.30(e)(2) — Governs interim responses to citizen petitions when a final decision cannot be made within the standard timeframe
","- The FDA has not made a decision due to other Agency priorities and numerous demands on the Agency’s resources.
- The petition requested assignment of a therapeutic equivalence evaluation code of ""AP"" to a specific indomethacin injection formulation (1 mg/5 mL, NDA 022536)
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3666-0004_Denial_Response_Letter_from_FDA_CDER_to_Fresenius_.pdf,3/11/2022,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- 21 CFR 314.3(b)
- Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) ","- The requested reference drug, Indocin (NDA 018878), is no longer marketed and was removed from the active list in the Orange Book in 2011.
- Products listed in the Discontinued Drug Product List cannot be assigned Therapeutic Equivalence (TE) Codes.
- Therefore, a TE Code (""AP"") cannot be assigned to Indomethacin with respect to Indocin.",FALSE,
FDA-2018-P-3691-0005_Letter_from_FDA_CDER_to_KVK_TECH__INC_.pdf,4/2/2019,,"Center for Drug Evaluation and Research (CDER)
",Approved (Determination Issued),"- FDA references the Approved Drug Products With Therapeutic Equivalence Evaluations (Orange Book).
- No specific CFR or U.S. Code citations are mentioned, but the context refers to regulatory listings in the Orange Book","- FDA reviewed its records and found that Chlor-Trimeton Allergy 12 Hour (chlorpheniramine maleate) 8 mg was not withdrawn from sale due to safety or effectiveness issues.
- As such, the drug will remain in the Discontinued Drug Product List.",FALSE,
FDA-2018-P-3709-0011_Interim_Response_Letter_from_FDA_CDRH_to_Jennifer_.pdf,3/4/2019,,Center for Devices and Radiological Health (CDRH),Interim Response,"21 CFR 10.30(e)(2) — FDA regulations on citizen petitions regarding interim responses
","- The petition raises issues requiring further review and analysis by FDA officials.
- Therefore, the FDA has issued an interim response and committed to reply again once a decision is reached
",FALSE,
FDA-2018-P-3709-0014_Final_Response_Letter_from_FDA_CDRH_to_Jennifer_Ne.pdf,7/12/2022,,"Center for Devices and Radiological Health (CDRH)
",Denied,"- 21 CFR 10.30(e)(3)
- 21 CFR 876.1500
- Section 516 of the FD&C Act (21 U.S.C. 360f)
- Section 501(g) of the FD&C Act (21 U.S.C. 351(g))
- Section 520(g) of the FD&C Act (21 U.S.C. 360j(g))
- 21 CFR 895.21(a)(1)
- 21 CFR 895.25
- 21 CFR 7.3(g), 7.3(m)(2)
- 21 CFR 820.30(c)","- The FDA concluded that the Permanent Cautery Instruments for Da Vinci Robotic Surgeries do not present an “unreasonable and substantial risk of illness or injury that cannot be remedied by labeling.”
- Cited MDRs show very low rates of adverse events with no confirmed injuries.
- Intuitive Surgical’s patent filings do not establish a design defect or safety issue.
- The cited study on leakage currents supports current use-life limitations and existing safeguards (e.g., kill switch) on instruments.
- AEM (Active Electrode Monitoring) technology was evaluated and found to offer no additional mitigation for the types of failures cited.
- FDA noted that the referenced recalls and regulatory actions did not demonstrate systemic or unresolved safety concerns; post-recall and inspection processes were appropriately followed and closed.
- FDA’s systematic review found the Da Vinci system had equal or better safety profiles compared to traditional surgery.
- The 2013 recall and subsequent inspections did not reveal deficiencies warranting a ban.",FALSE,
FDA-2018-P-3730-0005_Letter_from_FDA_CDER_to_Aziant_Drug_Research_Solut.pdf,2/4/2019,,"Center for Drug Evaluation and Research (CDER)
",Approved (Determination Issued),"- 21 U.S.C. §355(j)(7)
- 21 CFR 314.161
- 21 CFR 314.162","- The FDA reviewed the citizen petition and other information related to Esbriet (pirfenidone) 534 mg tablets.
- Determined that the drug was not withdrawn for safety or effectiveness reasons.
- Based on this, the drug remains listed in the “Discontinued Drug Product List” section of the Orange Book and can be referenced in Abbreviated New Drug Applications (ANDAs).
- Petition did not provide sufficient data or evidence to contradict this conclusion.
- The agency’s review also included publicly available data and product usage records confirming no safety or efficacy-related withdrawal occurred
",FALSE,
FDA-2018-P-3742-0004_Letter_from_FDA_CDER_to_Pharmacomechanics.pdf,3/29/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"21 CFR 10.30(e)(2) — FDA regulations concerning interim responses to citizen petitions.
","The petition raises complex issues requiring extensive review and analysis by FDA officials, hence the need for more time before issuing a final decision.

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3742-0005_Final_Response_from_FDA_CDER_to_Pharmacmechanics.pdf,9/8/2022,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- 21 CFR 211.194(a)(2)
- 21 CFR 211.160(b)(4)
- ICH Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions (November 2007)
- ICH Q4B Annex 7(R2) Dissolution Test General Chapter (June 2011)
- ICH Q2(R1) Validation of Analytical Procedures (November 2005)
- USP General Chapters: <711>, <1092>
- ASTM Standard E2503 (2007)","- FDA concluded that dissolution testing methods are scientifically valid and properly supported by guidance, standards, and compendial references.
- Apparatus used in testing are qualified and methods are validated according to cGMP.
- USP chapters and international harmonization through ICH demonstrate acceptance and standardization of the dissolution procedures.
- The claim that dissolution testers have never been validated misunderstands the distinction between method validation and instrument qualification.
- FDA affirmed that dissolution methods are not intended to identify unknown samples, but to assess quality and consistency.
- The FDA also reiterated that method verification is required for lab usage, even if a USP method is applied.
- FDA guidance documents and the Dissolution Methods Database remain valid and scientifically appropriate.",FALSE,
FDA-2018-P-3746-0005_Letter_re_Citizen_Petition_from_FDA_CDER_to_BF_Inn.pdf,10/23/2018,,"Center for Drug Evaluation and Research (CDER)
",Dismissed (moot),"Not Mentioned
","The petitioner requested that FDA designate fluticasone propionate ointment 0.005% (ANDA 076668 by Perrigo) as the reference standard in the Orange Book. The FDA had already updated the Orange Book to list Perrigo’s ANDA as the reference standard and moved NDA 019957 (previously listed) to the discontinued section. Therefore, the petition was dismissed as moot.

",FALSE,
FDA-2018-P-3770-0007_Letter_from_FDA_CDER_to_Luitpold_Pharmaceuticals_I.pdf,10/16/2020,"No date recognized by ChatGPT, but found in signature line.","Center for Drug Evaluation and Research (CDER)
",Approved,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)
- 505(j)(2)(A) and (B)
- 505(j)(2)(A)(iv)","- The proposed change in strength does not raise questions of safety or effectiveness.
- The dosage form, route, and indication are the same as the listed drug.
- The change is consistent with existing labeling and dosing recommendations.
- If bioequivalence is shown, it can be expected to have the same therapeutic effect.
- No new investigations are required to demonstrate safety or efficacy for the proposed strength",FALSE,
FDA-2018-P-3786-0006_Response_Letter_from_FDA_CDER_to_Hyman__Phelps___M.pdf,6/13/2023,"No date recognized by ChatGPT, but found in signature line.","Center for Drug Evaluation and Research (CDER)
",Approved,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)
- 21 CFR 314.94(a)(3)(iii)","- The proposed strength differs from the listed drug but does not pose questions of safety or effectiveness.
- The use, dosage form, route, and indication are the same as the reference drug.
- If bioequivalence is demonstrated, the product is expected to have the same therapeutic effect.
- No additional investigations are necessary to demonstrate safety or efficacy
",FALSE,
FDA-2018-P-3806-0003_Letter_from_FDA_CDER_to_Greg_Grillo.pdf,4/2/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"21 CFR 10.30(e)(2) – governing the provision of interim responses when decisions are pending
","The petition raises complex issues that require extensive review and analysis by FDA officials. The petitioner requested that the FDA regulate oral moisturizers marketed for dry mouth as drugs or devices due to their intended use and formulation requirements for safety
",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3806-0004_Response_letter_from_FDA_CDER_to_Greg_Grillo.pdf,11/9/2020,,"Center for Drug Evaluation and Research (CDER)
",Denied,"Not Mentioned
","- The petition requested FDA regulate oral moisturizers for dry mouth with low pH to ensure their safety.
- FDA concluded that the petition did not provide sufficient evidence that such products result in increased incidence of oral pathologies (e.g., dental caries).
- FDA noted that increased salivary activity might mitigate acidity-related risks.
- FDA stated that clinical data are needed to evaluate whether a pH standard is warranted.
- Because such data were not supplied, FDA declined to take action
",FALSE,
FDA-2018-P-3825-0004_180_Day_Interim_Response_Letter_from_FDA_CFSAN_to_.pdf,4/5/2019,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Interim Response,"- 21 C.F.R. § 101.11(o)(3)
- 21 U.S.C. § 371(h)(1)
- 21 C.F.R. § 10.30(e)(2)","FDA cites inability to reach a decision within the 180-day period due to competing agency priorities and limited resources. It commits to reviewing the petition and considering regulatory amendments in the context of other priorities.

",FALSE,
FDA-2018-P-3843-0114_Letter_from_FDA_CDRH_to_Hoomad_Noorchashm_Redacted.pdf,6/24/2019,,"Center for Devices and Radiological Health (CDRH)
",Interim Response,"21 CFR 10.30(e)(2)
","FDA is still reviewing and analyzing the issues raised in the petition, which requested banning the use of uncontained laparoscopic power morcellators in gynecological surgeries involving the uterus and associated tumors. This interim response is issued per regulation and final action will be communicated upon completion of the review.

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-3843-0115_Letter_from_FDA_to_Hoomad_Noorchashm.pdf,12/30/2020,,"Center for Devices and Radiological Health (CDRH)
",Denied,"- 21 C.F.R. § 10.30(e)(3)
- 21 CFR § 884.4050
- Section 516(a) of the FD&C Act, 21 U.S.C. 360f(a)
- 21 CFR 895.21(a)","- FDA determined that uncontained LPMs (Laparoscopic Power Morcellators) in gynecologic surgeries do not present a substantial deception or an unreasonable and substantial risk of illness or injury that cannot be mitigated through labeling changes.
- FDA has issued multiple communications and updated labeling guidance since 2014 to reduce the risks associated with LPM use.
- The agency found that enhanced labeling requirements, including use of containment systems and appropriate patient selection, are sufficient mitigations.
- The petitioner’s request did not meet the statutory criteria for a device ban.",FALSE,
FDA-2018-P-3861-0007_Citizen_Petition_Approval_from_FDA_CDER_to_Innogen.pdf,9/13/2023,"No date recognized by ChatGPT, but found in signature line.","Center for Drug Evaluation and Research (CDER)
",Approved,"- Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act
- 21 CFR 314.93
- 21 CFR 314.94(a)(3)(iii)
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)","- The proposed change in strength (from 250 mg and 500 mg to 125 mg) does not raise concerns regarding safety or effectiveness.
- The new strength is consistent with the dosing recommendations of the reference listed drug.
- If shown to meet bioequivalence, it can be expected to have the same therapeutic effect.
- No significant labeling changes or investigations are needed to demonstrate safety or efficacy.",FALSE,
FDA-2018-P-3883-0005_Letter_from_FDA_CDER_to_Foley___Lardner_LLP.pdf,4/4/2019,,"Center for Drug Evaluation and Research (CDER)
",Approved (Determination Issued),"Approved Drug Products With Therapeutic Equivalence Evaluations (commonly known as the Orange Book)
","The FDA reviewed its records and determined that CORTISPORIN otic solution (hydrocortisone/neomycin sulfate/polymyxin B sulfate) was not withdrawn from sale for reasons of safety or effectiveness. Therefore, the product will be listed in the “Discontinued Drug Product List” section of the Orange Book.

",FALSE,
FDA-2018-P-3896-0005_Interim_Response_from_FDA_CDRH_to_Chul_Hi_Park_Red.pdf,4/11/2019,,"Center for Devices and Radiological Health (CDRH)
",Interim Response,21 CFR 10.30(e)(2),"Decision pending due to complex issues requiring further agency review.



",FALSE,
FDA-2018-P-3896-0006_Petition_Response_from_FDA_CDRH_to_Chul_Hi_Park_Re.pdf,10/12/2021,,"Center for Devices and Radiological Health (CDRH)
",Denied,"- 21 CFR 878.4750 (Implantable staples)
- 21 CFR 878.3300 (Surgical mesh)
- 21 U.S.C. § 360c(a)(1) (Device classification)
- 21 U.S.C. §§ 360(k) and 360c(i) (Substantial equivalence & classification)
- 21 CFR Part 820 (Good Manufacturing Practices)
- 21 CFR Part 803 (Adverse Event Reporting)
- 21 CFR Part 801 (Labeling Requirements)
- 21 U.S.C. §§ 351 and 352 (Adulteration and Misbranding)
- Section 513(b) of the FD&C Act","- The petitions did not provide sufficient evidence that additional performance testing and risk analysis are required to ensure safety and effectiveness.
- FDA already evaluates performance data under its existing 510(k) review process.
- Surgical staplers for internal use were recently reclassified to Class II with special controls requiring more comprehensive data.
- Existing labeling and performance testing recommendations are deemed sufficient.
- FDA guidance (e.g., labeling for surgical staplers/staples for internal use) and public availability of summary SE data already address concerns.
- Evidence presented in the petitions (e.g., self-authored materials, general articles) did not substantiate the need for the requested administrative actions.",FALSE,
FDA-2018-P-3933-0003_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,2/27/2019,,"Center for Drug Evaluation and Research (CDER)
",Dismissed (moot),"- 21 CFR 10.30(e)(2)(iii)
","- The petition requested that FDA assign a therapeutic equivalence (TE) code for magnesium sulfate injection (10 gm/20 mL).
- FDA confirmed the TE code was already added to the Orange Book for NDA 19316 and ANDA 202411, making the request moot.
- As such, the FDA dismissed the petition because the requested action had already been completed.",FALSE,
FDA-2018-P-3949-0007_Letter_from_FDA_CDER_to_Lachman_Consultant_Service.pdf,4/18/2019,,"Center for Drug Evaluation and Research (CDER)
",Approved (Determination Issued),"Not Mentioned explicitly in the letter; however, reference is made to the Orange Book (Approved Drug Products With Therapeutic Equivalence Evaluations) and the Federal Register
","The FDA reviewed its records and found that TRISENOX (arsenic trioxide) injection, 1 mg/mL, was not withdrawn from sale for reasons of safety or effectiveness. As a result, it will remain in the “Discontinued Drug Product List” section of the Orange Book.
",FALSE,
FDA-2018-P-3951-0004_Interim_Response_Letter_from_FDA_CDRH_Redacted.pdf,4/16/2019,,"Center for Devices and Radiological Health (CDRH)
",Interim Response,"21 CFR 10.30(e)(2)
","The FDA has not reached a decision because the petition raises issues requiring further review and analysis. The interim response complies with FDA regulations on citizen petitions.

",FALSE,
FDA-2018-P-3951-0005_Petition_Response_from_FDA_CDRH_to_Chul_Hi_Park_Re.pdf,10/12/2021,,"Center for Devices and Radiological Health (CDRH)
",Denied,"- 21 CFR 878.4750 (Implantable staple)
- 21 CFR 878.3300 (Surgical mesh)
- 21 U.S.C. § 360c(a)(1) (Device classification)
- 21 U.S.C. §§ 360(k) and 360c(i) (Substantial equivalence – 510(k))
- 21 CFR Part 820 (Good Manufacturing Practice)
- 21 CFR Part 803 (Adverse Event Reporting)
- 21 CFR Part 801 (Labeling Requirements)
- 21 U.S.C. §§ 501 and 502 (Adulteration and Misbranding)
- 21 U.S.C. § 360c(b) (Device reclassification)","- The petitions did not provide sufficient evidence to require additional performance testing or labeling changes beyond existing regulations.
- FDA already requires and reviews risk analyses and performance data for 510(k) submissions, including benchtop, ex vivo, and in vivo studies.
- Surgical staplers for internal use were reclassified as class II devices with special controls (86 FR 56195), and FDA issued updated labeling guidance (86 FR 56272).
- Chronic animal studies and clinical trials are requested when necessary to evaluate device safety.
- FDA continues to monitor device safety post-clearance through adverse event reporting and market surveillance.
- Summary information about test data is publicly available via 510(k) summaries.
- The evidence provided by the petitioner, including self-authored analysis, lacked sufficient justification to mandate the changes requested.",FALSE,
FDA-2018-P-4088-0031_Letter__from_FDA_CDER_to_Data_Based_Medicine_Ameri.pdf,4/26/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"21 CFR 10.30(e)(2)
","The petition raises complex issues that require extensive review and analysis by Agency officials. The FDA has not reached a decision yet and is providing an interim response in accordance with its regulations.
",FALSE,
FDA-2018-P-4143-0012_Letter_from_FDA_CDRH_to_University_of_Toledo.pdf,4/2/2019,,"Center for Devices and Radiological Health (CDRH)
",Interim Response,"21 CFR 10.30(e)(2)
","The petition raises issues requiring further review and analysis by agency officials. The interim response was issued per regulatory procedures for citizen petitions.

",FALSE,
FDA-2018-P-4281-0006_Response_Letter_from_FDA_CDER_to_Fresenius_Kabi_US.pdf,5/27/2021,"No date recognized by ChatGPT, but found in signature line.","Center for Drug Evaluation and Research (CDER)
",Approved,"- Section 505(j)(2)(C) of the FDCA
- 21 CFR 314.93
- 21 CFR 314.93(e)(1)
- 21 CFR 314.94(a)(3)(iii)
- Section 505(j)(2)(A) and (B)
- Section 505(j)(2)(A)(iv)","- The change in strength does not raise safety or effectiveness concerns
- The use, dose, dosage form, and route are unchanged
- Proposed strength aligns with approved labeling
- Bioequivalence data will ensure therapeutic equivalence
- No new investigations are necessary for safety and effectiveness",FALSE,
FDA-2018-P-4306-0037_Interim_Response_from_FDA_CDER__re_Citizen_Petitio.pdf,5/7/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"21 CFR 10.30(e)(2)
","The FDA has not yet resolved the issues due to the need to address other Agency priorities and resource constraints. The interim response is provided under FDA regulations regarding citizen petitions and commits to responding as soon as possible.

",FALSE,
FDA-2018-P-4306-0050_Response_Letter_from_FDA_CDER_to_Jill_H__Osborne_R.pdf,5/24/2021,"Date was incorrectly identified by ChatGPT, but date has been manually adjusted.","Center for Drug Evaluation and Research (CDER)
",Denied,"Not explicitly cited in terms of legal statutes or CFR sections; references to labeling changes and approval documents include:
- NDA 20193
- sNDA 20193/S-14
- Labeling updates approved June 16, 2020 (link)
- FDA drug safety communication draft guidance: Drug Safety Information—FDA’s Communication to the Public (for internal policy context, not a statute)","- The petition requested warnings about retinal disease linked to Elmiron (pentosan polysulfate sodium) and recommendations for alternative therapies.
- FDA reviewed a range of data, including:
- The Pearce study on pigmentary maculopathy
- A user-conducted survey
- FDA's internal adverse event and utilization databases
- FDA acknowledged an association between long-term Elmiron use and pigmentary retinal changes, with uncertain visual outcomes.
- As of June 16, 2020, FDA approved labeling revisions that addressed most of the petition's concerns, including detailed warnings and monitoring recommendations.
- The request to recommend other therapies was denied because Elmiron is the only FDA-approved oral treatment for IC and such decisions are best left to physician-patient discussions.",FALSE,
FDA-2018-P-4338-0025_Agency_Response_Letter_from_FDA_CDER_to_PMRS.pdf,4/12/2019,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- Section 505(b), 505(j), and 505(q)(1)(F) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
- 21 CFR 314.105, 314.125, 314.127, 314.110, 314.200
- SUPPORT Act (Pub. L. 115-271, 132 Stat. 3894), particularly Section 3041","- FDA is required to take final action on petitions within 150 days under section 505(q)(1)(F), but this does not require them to make a final determination on an NDA.
- No final determination has been made regarding the approvability of NDA 209774 (MNK-812), so FDA denies the petition’s requests without comment.
- The petition repeated arguments from previous petitions (e.g., Remoxy ER), which were already denied.
- FDA maintains that decisions on the approvability of drug applications must follow the established review process under the FD&C Act and FDA regulations, not be made piecemeal.
- FDA continues to consider long-term use issues raised in other ongoing petitions, but this does not warrant separate action here.",FALSE,
FDA-2018-P-4454-0008_Letter_from_FDA_CFSAN_to_Bonumose_LLC.pdf,5/17/2019,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Interim Response,"- 21 CFR § 101.9(c)(6)(i)
- 21 CFR § 101.9(c)(6)(ii)
- 21 CFR § 101.9(c)(6)(iii)
- 21 CFR 10.30(e)(2)","The FDA stated it was unable to reach a decision within 180 days of receipt of the petition due to other agency priorities and limited resources. They assured that the review would be completed and regulatory amendments considered as warranted, within the context of CFSAN's other program priorities.

",FALSE,Appears to be a duplicate file of FDA-2018-P-4454-0009_Letter_from_FDA_CFSAN_to_Bonumose_LLC.pdf.
FDA-2018-P-4454-0009_Letter_from_FDA_CFSAN_to_Bonumose_LLC.pdf,5/17/2019,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Interim Response,"- 21 CFR § 101.9(c)(6)(i)
- 21 CFR § 101.9(c)(6)(ii)
- 21 CFR § 101.9(c)(6)(iii)
- 21 CFR 10.30(e)(2)","The FDA stated it was unable to reach a decision within 180 days of receipt of the petition due to other agency priorities and limited resources. They assured that the review would be completed and regulatory amendments considered as warranted, within the context of CFSAN's other program priorities.

",FALSE,Appears to be a duplicate file of FDA-2018-P-4454-0008_Letter_from_FDA_CFSAN_to_Bonumose_LLC.pdf.
FDA-2018-P-4454-0011_Final_Response_Letter_from_FDA_CFSAN_to_Bonumose_L.pdf,6/11/2021,,"Center for Food Safety and Applied Nutrition (CFSAN)
",Denied,"- 21 CFR § 101.9(c)(6)(i)
- 21 CFR § 101.9(c)(6)(ii)-(iii)
- 21 CFR 101.80(c)(2)(ii)
- 21 CFR 10.30(e)(3)
- 21 U.S.C. § 343(q)(1)(D)","- The petition sought to: (a) amend the definition of dietary fiber to include small carbohydrates like D-tagatose, (b) classify D-tagatose as a dietary fiber, and (c) amend the definitions of total and added sugars.

- The FDA denied the requests for the following reasons:
• There is no new scientific evidence sufficient to support amending the definition of dietary fiber (which includes non-digestible carbohydrates with 3+ monomeric units).
• The petition does not provide new data demonstrating physiological effects of D-tagatose that would support its inclusion.
• FDA's existing definition aligns with international guidelines and IOM recommendations.
• There is a lack of consensus and consistent scientific basis for including monosaccharides like D-tagatose as dietary fiber.
• FDA emphasized that the dietary fiber definition is science-based, not method-dependent, and they see no valid justification to change the ""3 or more monomeric units"" criterion.
• FDA also did not support redefining total or added sugars to exempt beneficial sugars like D-tagatose.
• However, FDA did acknowledge that further information may be needed and published a Request for Information (RFI) for public comment to explore sugars metabolized differently from traditional sugars (e.g., D-tagatose, allulose).",FALSE,
FDA-2018-P-4490-0006_Citizen_Petition_Denial_Response_Letter_from_FDA_C.pdf,3/29/2019,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- Section 505(b), (c)(1)(A), and (d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355)
- 21 CFR 314.125(b)
- 21 CFR 314.126
- 21 CFR 201.57
- 21 CFR 201.100(c)(1) ","- Substantial Evidence: The FDA found that the original clinical trials provided substantial evidence of efficacy for the target population (adult women <65 with IBS-C). Post hoc subgroup analyses confirmed similar efficacy in this subgroup.
- CV Risk Considerations: The FDA concluded that cardiovascular risks could be mitigated through labeling (e.g., contraindications, warnings) and did not warrant REMS or use restrictions.
- No Need for New Trials: Existing data, even if based on earlier standards (e.g., Rome II criteria), remain clinically meaningful and relevant. A new postmarketing trial was deemed unnecessary.
- Labeling Sufficiency: The FDA stated the labeling adequately communicates the limitations and risks, and additional strategies like REMS were not warranted. ",FALSE,
FDA-2018-P-4549-0007_Interim_Response_Letter_for_FDA_2018_P_4549.pdf,5/23/2019,,"Center for Drug Evaluation and Research (CDER)
",Interim Response,"21 CFR 10.30(e)(2)
","The FDA stated that it had not yet resolved the issues raised in the petition due to the complex nature of the request, which required extensive review and analysis by Agency officials. The petition asked the Agency to designate an additional reference standard for Terbinafine Tablets in the Orange Book to support ANDA submissions.

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-4549-0009_Response_Letter_from_FDA_CDER_to_Unichem_Pharmaceu.pdf,4/28/2020,,"Center for Drug Evaluation and Research (CDER)
",Approved,"- Section 505(j) of the FD&C Act (21 U.S.C. 355(j))
- 21 CFR 314.3(b)
- 21 CFR 314.94(a)(3)
- 21 CFR 314.161(a)(1)
- 21 CFR 314.122(c)
- 21 CFR 314.127(a)(11)","- The original reference standard (Lamisil, NDA 020539 by Novartis) is no longer available on the market.
- Aurobindo’s ANDA 078297 product became the market leader between April–June 2019.
- It is therapeutically equivalent (coded ""AB"" in the Orange Book).
- FDA found it appropriate to select Aurobindo’s product as the new reference standard for bioequivalence studies.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-4590-0005_Letter_from_FDA_CDER_to_Ascend_Laboratories__LLC.pdf,5/22/2019,,"Center for Drug Evaluation and Research (CDER)
",Denied,"- Controlled Substances Act (CSA)
- 21 CFR § 1308/1308.43 (DEA petition process)
- 83 FR 48950 (DEA Final Order, Sep. 28, 2018)","- The DEA’s final order (Sep. 28, 2018) covers only FDA-approved drugs that contain CBD derived from cannabis with ≤0.1% THC, and places those in Schedule V.
- Petitioner's request was for a generic version of Epidiolex using synthetic CBD.
- Synthetic CBD is not covered under the DEA’s existing order.
- FDA stated that DEA is the proper authority for scheduling actions and advised petitioner to submit the request to DEA.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-4591-0003_Interim_Response_Letter_from_FDA_CFSAN_to_Internat.pdf,,No date recognized by ChatGPT nor apparent through a quick skim.,"Center for Food Safety and Applied Nutrition (CFSAN)
",Interim Response,"Title 21 of the Code of Federal Regulations, Section 10.30(e)(2); Regulation 168.140 (legal definition for pure maple syrup)
","The FDA states it has not been able to reach a decision within the first 180 days due to other agency priorities and limited resources. The review is ongoing.

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-4642-0005_Agency_Response_Letter_from_FDA_CVM_to_Provetica_A.pdf,2/21/2019,"No date recognized by ChatGPT, but found in signature line.","Center for Veterinary Medicine (CVM)
",Approved,"- Section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act
- Section 512(n)(3)(C) of the Act
- 21 CFR 514.5","- The proposed changes (dosage form: oral solution instead of capsules) can be considered under a suitability petition.
- The changes do not require new investigations to demonstrate safety and effectiveness.
- The petition meets the criteria of section 512(n)(3)(C) of the FD&C Act for approval of a suitability petition.
- Approval of the petition allows submission of an abbreviated new animal drug application (ANADA), but does not guarantee approval of the ANADA itself.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-4656-0006_Letter_from_FDA_CVM_to_Animal_Legal_Defense_Fund.pdf,5/20/2019,,Center for Veterinary Medicine (CVM),Denied,"- 21 CFR 10.35(e) (Petitions for stay of action)
- 21 U.S.C. § 512 (Federal Food, Drug, and Cosmetic Act - FFDCA)
- 21 CFR 514.4 (Substantial evidence of effectiveness)
- National Environmental Policy Act (NEPA)
- Endangered Species Act (ESA)
- 40 CFR 1508.27(b)(1), (b)(9)
- 50 CFR 402.03","- The petition did not meet the necessary criteria under 21 CFR 10.35 to justify a stay of action.
- FDA concluded the petition failed to demonstrate irreparable harm, serious public health concern, or substantial legal violations.
- FDA affirmed that it complied with all applicable legal and regulatory requirements in the approval of Experior™ (a beta-agonist for cattle) including the FFDCA, NEPA, and ESA.
- Detailed studies demonstrated safety to target animals, food safety, human safety, and environmental impact.
- FDA's issuance of a Finding of No Significant Impact (FONSI) was justified based on a comprehensive Environmental Assessment.
- No additional Environmental Impact Statement was warranted, and the analysis included effects on threatened and endangered species.
- Assertions made by the petition lacked adequate evidence or were speculative.",FALSE,
FDA-2018-P-4661-0004_Letter_from_FDA_CDER_to_Hyman__Phelps___McNamara__.pdf,5/31/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2)
","The FDA has not reached a decision due to the need to prioritize other agency matters. The interim response is issued under FDA regulations to inform the petitioner that a final decision is pending due to numerous demands on the Agency’s resources.

",FALSE,
FDA-2018-P-4661-0005_Letter_from_FDA_CDER_to_Hyman__Phelps___McNamara__.pdf,10/16/2019,,Center for Drug Evaluation and Research (CDER),Dismissed (moot),"The Orange Book is referenced (Approved Drug Products With Therapeutic Equivalence Evaluations); specific statutes or regulations are not cited directly in the document.
","The petition was dismissed because the FDA determined that the distribution of the current reference standard (diclofenac potassium tablets, 50 mg, approved under ANDA 075463) resumed after the petition was filed.

",FALSE,
FDA-2018-P-4664-0003_Letter_from_FDA_CDER_to_Fresenius_Kabi_USA__LLC.pdf,5/31/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2)
","The petition raises complex issues requiring extensive review and analysis by Agency officials. The interim response is provided in accordance with FDA regulations.

",FALSE,
FDA-2018-P-4714-0016_Letter_from_FDA_CDER_to_TherapeuticsMD__Inc_.pdf,6/10/2019,"Date was originally incorrect, so have updated to be accurate",Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2)
","The FDA has not yet resolved the issues raised because the petition raises complex issues requiring extensive review and analysis by Agency officials. The interim response was issued in accordance with FDA regulations on citizen petitions to acknowledge the petition within a specified timeframe.

",FALSE,
FDA-2018-P-4769-0003_Letter_from_FDA_CDER_to_Exela_Pharma_Sciences__LLC.pdf,6/13/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2)
","The petition raises complex issues that require extensive review and analysis by Agency officials. The FDA is still evaluating the request and will respond once a decision is reached.

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-4812-0004_Letter_from_FDA_CDER_to_Arent_Fox_LLP.pdf,6/11/2019,,Center for Drug Evaluation and Research (CDER),Denied,"Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book); reference to the Federal Register notice
","FDA reviewed records and determined that Nizoral (Ketoconazole) topical cream, 2% was not withdrawn for reasons of safety or effectiveness. As a result, the drug will remain listed in the “Discontinued Drug Product List” section of the Orange Book, meaning it may still serve as a reference product for generic applications. 

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-4832-0004_Interim_Response_Letter_from_FDA_CDER_to_Goodwin_P.pdf,6/17/2019,,Center for Drug Evaluation and Research (CDER),Interim Response,"21 CFR 10.30(e)(2)
","The FDA has not yet resolved the issues raised in the petition because it involves complex issues that require extensive review and analysis by Agency officials. The interim response is issued per 21 CFR 10.30(e)(2).

",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-4832-0005_Final_Response_Letter_from_FDA_CDER_to_Goodwin_Pro.pdf,10/2/2024,,Center for Drug Evaluation and Research (CDER),Denied,"- Section 505(b)(2) of the FD&C Act
- 21 CFR § 314.3(b) (definitions, including pharmaceutical equivalents)
- Orange Book Preface references (e.g., 43rd and 44th editions)
- FDA Guidance for Industry:
- Levothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date (July 2001)
- Levothyroxine Sodium Tablets—In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing (Dec. 2000)
- Applications Covered by Section 505(b)(2) (Oct. 1999)
- Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors (May 2022)","- FDA reviewed and considered the color-coded blister packaging and determined it was sufficient to mitigate risks of medication errors, despite the lack of coloring on the tablets themselves.
- The Agency reviewed postmarketing safety data and found only two cases referencing tablet confusion, neither involving adverse events.
- FDA concluded the TE (Therapeutic Equivalence) code ""AB2"" was appropriate based on demonstrated bioequivalence with the reference listed drugs (RLDs).
- FDA emphasized that pharmaceutical equivalents may differ in tablet color and still meet bioequivalence standards.
- The request to prevent approval of future supplemental NDAs related to bulk packaging was denied, as these are reviewed on a case-by-case basis.",FALSE,"Missing in original spreadsheet, so completed in full here. "
FDA-2018-P-4851-0009_Letter_from_FDA_CDER_to_Hetero_Labs_Ltd___Hetero_U.pdf,5/30/2019,,Center for Drug Evaluation and Research (CDER),Approved (Determination Issued),"- Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book)
- Federal Register notice (enclosure referenced)","The FDA reviewed records and determined that Lupron (1 mg/0.2 mL) was not withdrawn for reasons related to safety or efficacy. Therefore, the product should remain listed appropriately in the Orange Book under the discontinued section.

",FALSE,"Missing in original spreadsheet, so completed in full here. "